

MICROORGANISM PRODUCING O-ACETYL HOMOSERINE AND THE METHOD OF PRODUCING O-ACETYL HOMOSERINE USING THE SAME

TECHNICAL FIELD

The present invention relates to a microorganism of *Escherichia* sp. producing *O*-acetyl homoserine, and a method of producing *O*-acetyl homoserine in high yield using the microorganism.

BACKGROUND ART

O-Acetyl homoserine acts as a precursor of methionine, which is one of the essential amino acids in the body. Methionine has been widely used as a component of medical infusion solutions and raw materials for medicinal products as well as an animal feed and food additive.

Methionine can be biologically or chemically synthesized. Recently, a two-step process, in which an L-methionine precursor produced by fermentation is converted to L-methionine by an enzyme reaction, was disclosed (International Publication No. WO 2008/013432). In the above two-step process, *O*-succinyl homoserine and *O*-acetyl homoserine may be used as the methionine precursor, and it is important that *O*-acetyl homoserine be produced in high yield for large-scale cost-effective production of methionine.

DISCLOSURE

Technical Problem

The present inventors, while endeavoring to improve the production of *O*-acetyl homoserine, discovered that the reduction of the expression or activity of citrate synthase protein can significantly increase the production capability of *O*-acetyl homoserine, thereby completing the present invention.

Technical Solution

An object of the present invention is to provide an *O*-acetyl homoserine-producing microorganism with improved *O*-acetyl homoserine production capability.

Another object of the present invention is to provide a method for producing *O*-acetyl homoserine using the microorganism.

Advantageous Effects

The use of the microorganism with *O*-acetyl homoserine production capability according

to the present invention can produce *O*-acetyl homoserine in a higher yield and in a more environmentally friendly manner than chemical synthesis. Additionally, the thus produced *O*-acetyl homoserine can be used as a precursor for the synthesis of methionine and acetic acid by *O*-acetyl homoserine sulfhydrylase, thereby enabling bioconversion of L-methionine, and the thus converted L-methionine can be widely used in the production of foods or food additives for humans as well as animal feeds or animal feed additives.

DESCRIPTION OF DRAWINGS

FIG. 1 is an expression cassette design for the construction of a microorganism with an attenuated activity of citrate synthase.

FIG. 2 is a restriction map of *pBAD24*-citrate synthase antisense RNA (asRNA) vector.

BEST MODE

In an aspect, the present invention provides a microorganism of *Escherichia* sp. producing *O*-acetyl homoserine, in which the activity of endogenous citrate synthase protein is attenuated or inactivated.


As used herein, the term “*O*-acetyl homoserine”, being a specific intermediate material in a methionine biosynthesis pathway of a microorganism, refers to an acetyl-derivative of L-homoserine. *O*-acetyl homoserine can be produced by an enzyme activity of transferring an acetyl group from acetyl-CoA to homoserine using homoserine and acetyl-CoA as substrates.

As used herein, the term “a microorganism producing *O*-acetyl homoserine” includes a microorganism, which, being a eukaryotic or prokaryotic microorganism producing *O*-acetyl homoserine within a living organism, is provided with *O*-acetyl homoserine-producing capability to its parent microorganism without *O*-acetyl homoserine-producing capability, or a microorganism which is endogenously provided with the *O*-acetyl homoserine-producing capability.

O-Acetyl homoserine-producing capability may be provided or promoted by improvement of species. The microorganisms having the *O*-acetyl homoserine-producing capability may include microorganism belonging to *Escherichia* sp., *Erwinia* sp., *Serratia* sp., *Providencia* sp., *Corynebacteria* sp., *Pseudomonas* sp., *Leptospira* sp., *Salmonella* sp., *Brevibacteria* sp., *Hypomononas* sp., *Chromobacterium* sp., and *Norcardia* sp., or fungi, or yeasts; specifically, microorganism belonging to *Escherichia* sp., *Corynebacteria* sp., *Leptospira* sp., and yeasts; and more specifically, microorganism belonging to *Escherichia* sp., as a specific example, *Escherichia coli*. The microorganisms having the *O*-acetyl homoserine-producing

capability may be microorganisms producing L-lysine, L-threonine, L-isoleucine, or L-methionine, or derivatives thereof, but are not limited thereto.

As used herein, the term “citrate synthase (E.C. 2.3.3.1)” refers to an enzyme in the first step of the TCA cycle that mediates the reaction between oxaloacetate and acetyl-CoA. Specifically, citrate synthase mediates the condensation reaction between an acetate residue having two carbon atoms, which is in acetyl-CoA, and oxaloacetate having four carbon atoms, thereby generating a citrate having six carbon atoms. In *Escherichia coli*, citrate synthase is designated GltA, and citrate synthase and GltA are interchangeably used in the present invention.



Specifically, citrate synthase may be one derived from *Escherichia* sp., and more specifically, GltA derived from *Escherichia coli*. Citrate synthase may be a protein comprising an amino acid sequence represented by SEQ ID NO: 4 or those having a homology of 70% or higher with amino acid sequence of SEQ ID NO: 4, specifically 80% or higher, or more specifically, 90% or higher. Additionally, as a sequence having a homology, if the amino acid sequence is one having the same or corresponding activity of citrate synthase with that of SEQ ID NO: 4, it is obvious that amino acid sequences with a deletion, a modification, a substitution, or an addition, in part of the sequences should also be included in the scope of the present invention. Additionally, based on the genetic code degeneracy, polynucleotide sequences encoding the same amino acid sequence and variants thereof should also be included in the scope of the present invention.

As used herein, the term “endogenous” activity refers to a natural state of a protein in a microorganism or an activity state of the corresponding protein provided in the microorganism before modification.

The “the attenuation or inactivation of a protein activity compared to its endogenous activity” refers to a reduction or elimination of the protein activity when compared with that possessed in its natural state. The attenuation is a concept referring to a case when the activity of a protein is reduced compared with that originally possessed by the microorganism due to a modification in the protein-encoding gene, a case when the level of overall protein expression is lower than that of the natural type strain of the microorganism, or a combination thereof, but is not limited thereto. The inactivation includes a case when the gene encoding the protein is not expressed at all compared to that of the natural type strain, and a case when the gene is expressed but exhibits no activity.

The attenuation or inactivation of a protein activity may be achieved by various methods well known in the art. Examples of the methods may include a method of replacing the gene encoding the protein on the chromosome with a gene modified so that the enzyme activity can be reduced including the case when the protein activity is removed; a method of introducing a modification on the expression-regulating sequence of the gene encoding the protein on the chromosome; a method of replacing the expression-regulating sequence of the gene encoding the protein with a sequence having a weak activity or no activity; a method of deleting a part of or the entire gene encoding the protein on the chromosome; a method of introducing an antisense oligonucleotide (e.g., antisense RNA), which inhibits the translation from the mRNA into a protein via a complementary binding to the transcript of the gene on the chromosome; a method of making the attachment of ribosome impossible by forming a secondary structure by artificially adding a Shine-Dalgarno (SD) sequence and its complementary sequence on the front end of the SD sequence of the gene encoding the protein; a method of reverse transcription engineering (RTE), which adds a promoter so as to be reversely transcribed on the 3' terminus of the open reading frame (ORF) of the corresponding sequence, etc., and also include a combination thereof, but are not limited thereto.

Specifically, the method of deleting a part of or the entire gene encoding a protein may be performed by replacing the polynucleotide, encoding the endogenous target protein within the chromosome via a vector for inserting chromosome into a microorganism, with a polynucleotide or a marker where part of the polynucleotide sequence is deleted. For example, a method of gene deletion via homologous recombination may be used, but is not limited thereto. Additionally, as used herein the term "part", although it may vary depending on the kinds of polynucleotide, may specifically refer to 1 nucleotide to 300 nucleotides, more specifically 1 nucleotide to 100 nucleotides, and even more specifically 1 nucleotide to 50 nucleotides, but is not limited thereto.

Additionally, the method of modifying the expression regulation sequence may be performed by inducing a variation on the expression regulation sequence of the polynucleotide sequence via deletion, insertion, conservative substitution, non-conservative substitution, or a combination thereof so as to further attenuate the activity of the expression regulation sequence; or by replacing the polynucleotide sequence with a polynucleotide sequence with a weaker activity. The polynucleotide sequence may include a promoter, an operator sequence, a sequence encoding a ribosome-binding domain, and a sequence for regulating termination of transcription and translation, but is not limited thereto.

Additionally, the method of modifying the gene sequence on the chromosome may be

performed by inducing a variation in the sequence via deletion, insertion, conservative substitution, non-conservative substitution, or a combination thereof so as to further attenuate the activity of the expression regulation sequence; or by replacing the sequence with a gene sequence improved to have a weaker activity or a gene sequence improved to have no activity, but is not limited thereto.

Specifically, for the attenuation of the activity of citrate synthase protein, part of an amino acid(s) in the amino acid sequence of the citrate synthase protein may be substituted with other amino acid(s). More specifically, a citrate synthase having an amino acid sequence, in which the 145th amino acid or the 167th amino acid in the amino acid sequence of the citrate synthase protein is substituted from tyrosine (Y) or lysine (K) to other amino acid(s) may be included. Even more specifically, the citrate synthase may be one having a gene sequence encoding a modified polypeptide, in which the 145th amino acid in the amino acid sequence of the citrate synthase protein is substituted from tyrosine (Y) to alanine (A), and the 167th amino acid is substituted from lysine (K) to alanine (A). In particular, the amino acid residue number was determined in sequential order after setting the amino acid positioned next to the methionine, which is encoded by the initiation codon, as the 1st amino acid. The polypeptide may respectively have an amino acid sequence represented by SEQ ID NO: 1 or 2. Additionally, if the activity of the citrate synthase is weaker than that of a wild-type, the citrate synthase may include amino acid sequences having a homology of 80% or higher with the amino acid sequence of SEQ ID NO: 1 or 2, specifically 90% or higher, more specifically 95% or higher, and even more specifically 97% or higher. As a sequence having a homology, if the amino acid sequence is one which has substantially the same or corresponding biological activity of a protein of SEQ ID NO: 1 or 2, it is obvious that amino acid sequences with a deletion, a modification, a substitution, or an addition in part of the sequences should also be included in the scope of the present invention.

As used herein, the term “homology” refers to a percentage in identity between two polynucleotides or polypeptide moieties. The homology between sequences from a moiety to another moiety may be determined by a technology known in the art. For example, the homology may be determined by directly arranging the sequence information between two different polynucleotide molecules or two different polypeptides using a computer program arranging and easily obtaining the sequence information. The computer program may include BLAST (NCBI), CLC Main Workbench (CLC bio), MegAlign™ (DNASTAR Inc), etc. Additionally, the homology between polynucleotides may be determined by hybridizing the

polynucleotides under the condition of forming a stable double strand between homologous regions, decomposing with a single-strand-specific nuclease, and determining the decomposed fragments.

As used herein, the term “homology” refers to a relationship between proteins having “common evolutionary origin” including homologous proteins derived from superfamily proteins in all grammatical forms or with spelling variations, and those derived from different species. These proteins (and the genes encoding the same) have sequence homologies reflected by high levels of sequence similarities. However, the term “homology”, for its general use and the use in the present invention, would refer to a sequence similarity when modified by an adjective such as “very high”, instead of referring to common evolutionary origin.

In an exemplary embodiment of the present invention, the microorganism may be one in which the activity of cystathionine gamma synthase (EC 2.5.1.48), homoserine kinase (EC 2.7.1.39), or the activities of both are weaker than their endogenous activities, or inactivated.

As used herein, the term “cystathionine gamma synthase” refers to an enzyme which can synthesize cystathionine by a chemical reaction described below, using *O*-succinyl homoserine and L-cysteine as substrates. In the present invention, the cystathionine gamma synthase from *E. coli*, is designated as “MetB”.

O-succinyl-L-homoserine + L-cysteine → L-cystathionine + succinate

Specifically, the cystathionine gamma synthase from *E. coli*, although not particularly limited thereto, may be a protein comprising an amino acid sequence represented by SEQ ID NO: 9 or those having a homology of 70% or higher with the amino acid sequence of SEQ ID NO: 9, specifically 80% or higher, and more specifically 90% or higher. Additionally, as a sequence having a homology, if the amino acid sequence is one having the same or corresponding activity of homoserine kinase with the amino acid sequence of SEQ ID NO: 9, it is obvious that amino acid sequences with a deletion, a modification, a substitution, or an addition in part of the sequences should also be included in the scope of the present invention. Additionally, based on the genetic code degeneracy, polynucleotide sequences encoding the same amino acid sequence and variants thereof should also be included in the scope of the present invention.

The method for attenuation and inactivation of the cystathionine gamma synthase activity may be performed according to the method described above.

As used herein, the term “homoserine kinase” refers to an enzyme causing the phosphorylation of homoserine, which performs the chemical reaction described below. In the present invention, the homoserine kinase from *E. coli*, is designated as “ThrB”.



Specifically, homoserine kinase from *Escherichia* sp., although not particularly limited thereto, may be a protein comprising an amino acid sequence represented by SEQ ID NO: 11 or those having a homology of 70% or higher with the amino sequence of SEQ ID NO: 11, specifically 80% or higher, or more specifically, 90% or higher. Additionally, as a sequence having a homology, if the amino acid sequence is one having the same or corresponding activity of homoserine kinase with the amino sequence of SEQ ID NO: 11, it is obvious that amino acid sequences with a deletion, a modification, a substitution, or an addition in part of the sequences should also be included in the scope of the present invention. Additionally, based on the genetic code degeneracy, polynucleotide sequences encoding the same amino acid sequence and variants thereof should also be included in the scope of the present invention.

The method for attenuation and inactivation of the homoserine kinase activity may be performed according to the method described above.

In a specific aspect of the present invention, the microorganism may be one, in which the activity of homoserine *O*-acetyltransferase is further introduced or enhanced, or the endogenous homoserine *O*-succinyltransferase is further modified to have the activity of homoserine *O*-acetyltransferase.

As used herein, the term “homoserine *O*-acetyltransferase (EC 2.3.1.31)” refers to an enzyme having an activity of transferring an acetyl group from acetyl-CoA to homoserine.

Specifically, the microorganism according to the present invention may be introduced with the activity of homoserine *O*-acetyltransferase. The homoserine *O*-acetyltransferase may be derived from various microorganism species, for example, from a microorganism selected from *Corynebacteria* sp., *Leptospira* sp., *Deinococcus* sp., *Deinococcus* sp., *Pseudomonas* sp., and *Mycobacterium* sp. Specifically, the homoserine *O*-acetyltransferase may be those which include the amino acid sequences represented by SEQ ID NO: 13 (*Leptospira meyeri*), SEQ ID NO: 14 (*Corynebacterium glutamicum*), or SEQ ID NO: 15 (*Deinococcus radiodurans*), but is

not limited thereto. Additionally, the homoserine *O*-acetyltransferase may be a protein comprising the above amino acid sequences or those having a homology of 70% or higher with the above amino acid sequences, specifically 80% or higher, or more specifically, 90% or higher. Additionally, based on the genetic code degeneracy, polynucleotide sequences encoding the same amino acid sequence and variants thereof should also be included in the scope of the present invention.

Examples of the homoserine *O*-acetyltransferase to be used in the present invention are disclosed in Korean Patent Application Publication No. 10-2011-0023703 and European Patent Application Publication No. EP 2290051, and the entire specifications of these patent documents may be included as references in the present invention.

Additionally, the protein, in which the endogenous homoserine *O*-succinyltransferase (EC 2.3.1.46) is modified to have the activity of homoserine *O*-acetyltransferase, refers to a polypeptide, in which the substrate specificity of the polypeptide having the homoserine *O*-succinyltransferase activity is changed from succinyl-CoA to acetyl-CoA. Additionally, the modified protein, although not particularly limited thereto, may be a polypeptide having homoserine *O*-acetyltransferase activity, unlike its wild-type, by replacing part of the amino acid sequence of the polypeptide having homoserine *O*-succinyltransferase activity.

Examples of the homoserine *O*-succinyltransferase may be a polypeptide from *Enterobacteria* sp., *Salmonella* sp., *Pseudomonas* sp., *Bacillus* sp., or *Escherichia* sp., specifically, a polypeptide from *Escherichia* sp. having the homoserine *O*-succinyltransferase activity, for example, a polypeptide having homoserine *O*-succinyltransferase activity from *E. coli*. More specifically, the homoserine *O*-succinyltransferase from *E. coli* may have the amino acid sequence represented SEQ ID NO: 16, but is not limited thereto. The homoserine *O*-succinyltransferase from *E. coli* is designated as "MetA".

The modified homoserine *O*-succinyltransferase may be a variant polypeptide, in which the 111th amino acid of the polypeptide represented by SEQ ID NO: 16 or polypeptides having a homology of 95% or above with the polynucleotide sequence of SEQ ID NO: 16 is substituted with glutamic acid, and additionally, the 112nd amino acid is substituted with threonine or histidine. Specifically, the variant polypeptide may be a polypeptide having the amino acid sequence of any of SEQ ID NOS: 17 to 19. Additionally, the variant polypeptide may be a protein comprising an amino acid sequence having a homology of 70% or higher with the above amino acid sequence, specifically 80% or higher, or more specifically 90% or higher. Additionally, based on the genetic code degeneracy, polynucleotide sequences encoding the

same amino acid sequence and variants thereof should also be included in the scope of the present invention. The information on the modified homoserine *O*-succinyltransferase can be obtained from Korean Patent Application Publication No. 10-2012-0070531 or International Publication No. WO2012/087039, and the entire specifications of these patent documents are included as references to the present invention.

As used herein, the term “introduction or enhancement of activity” refers to providing the activity of a particular protein to a microorganism which does not possess the protein; or enhancement of the intracellular activity of the protein in the microorganism which possesses the protein, and the like, and refers to the increase of the intracellular activity of the protein compared to the endogenous activity of the protein.

As used herein, the term “introduction or enhancement of protein activity” refers to not only the drawing of a higher effect than the original function due to the increase in the activity of the protein itself, but also the increase in the activity of the protein due to the increase in endogenous gene activity, endogenous gene amplification by the internal or external factors, the increase in copy number, gene introduction from outside, increase in enzyme activity due to the substitution, modification, or mutation, etc., but is not limited thereto.

In the above, the increase in gene copy number, although not particularly limited thereto, may be performed in a state operably connected to a vector, or by being inserted into the chromosome within a host cell. Specifically, the method may be executed by introducing a vector, which a polynucleotide encoding the protein of the present invention is operably connected to and can be replicated and function irrespective of a host, into a cell of the host; or introducing a vector, to which the polynucleotide is operably connected, inserting the polynucleotide into the chromosome of the host cell, into the host cell, thereby increasing the number of gene copies within the chromosome of the host cell.

The vector is a DNA construct including the polynucleotide sequence of the polynucleotide encoding the target protein, which is operably connected to a suitable regulation sequence so that the target protein can be expressed in an appropriate host, wherein the regulation sequence includes a promoter initiating transcription, a random operator sequence for regulation of the transcription, a sequence encoding a suitable mRNA ribosome-binding domain, and a sequence for regulation of transcription and translation. The vector, after being transformed into a suitable host cell, may be replicated or function irrespective of the host genome, or may be integrated into the host genome itself.

The vector used in the present invention may not be specifically limited as long as the

vector is replicable in the host cell, and any vector known in the art may be used. Examples of the vector may include natural or recombinant plasmids, cosmids, viruses, and bacteriophages. For example, as a phage vector or cosmid vector, *pWE15*, *M13*, *λMBL3*, *λMBL4*, *λIXII*, *λASHII*, *λAPII*, *λt10*, *λt11*, *Charon4A*, *Charon21A*, etc., may be used; and as a plasmid vector, *pBR*-based, *pUC*-based, *pBluescriptII*-based, *pGEM*-based, *pTZ*-based, *pCL*-based, *pET*-based, etc., may be used. Specifically, *pDZ*, *pACYC177*, *pACYC184*, *pCL*, *pECCG117*, *pUC19*, *pBR322*, *pMW118*, *pCC1BAC* vectors, etc., may be used.

Additionally, a polynucleotide encoding an endogenous target protein may be substituted with a modified polynucleotide using a vector for inserting into the chromosome of a microorganism. The insertion of the polynucleotide into the chromosome may be performed using a known method in the art, for example, by homologous recombination. Since the vector of the present invention can be inserted into the chromosome via homologous recombination, a selection marker for confirmation of the insertion into the chromosome may be additionally included. The selection marker is used for selection of a transformed cell, i.e., in order to confirm whether the target polynucleotide has been inserted, and markers providing selectable phenotypes such as drug resistance, nutrient requirement, resistance to cytotoxic agents, and expression of surface proteins may be used, but are not limited thereto. Under the circumstances where selective agents are treated, only the cells expressing the selection markers can survive or express other phenotypic traits, and thus the transformed cells can be easily selected.

As used herein, the term “transformation” refers to a process of introducing a vector including a polynucleotide encoding a target protein into a host cell thereby enabling the expression of the polynucleotide encoded by the protein in the host cell. For the transformed polynucleotide, it does not matter whether it is inserted into the chromosome of a host cell and located therein and located outside the chromosome, as long as it can be expressed in the host cell. Additionally, the polynucleotide includes DNA and RNA which encode the target protein. The polynucleotide may be inserted in any form insofar as it can be introduced into a host cell and expressed therein. For example, the polynucleotide may be introduced into a host cell in the form of an expression cassette, which is a genetic construct including all essential elements required for self-expression. The expression cassette may conventionally include a promoter operably connected to the polynucleotide, a transcription termination signal, a ribosome-binding domain, and a translation termination signal, and may be in the form of an expression vector capable of self-replication. Additionally, the polynucleotide may be introduced into a host cell as it is, and operably connected to a sequence essential for its expression in the host cell.

Additionally, as used herein, the term “operably connected” refers to a functional connection between a promoter sequence, which initiates and mediates the transcription of the polynucleotide encoding the target protein, and the gene sequence.

Then, the modification of the expression regulation sequence for increasing the expression of the polynucleotide, although not particularly limited thereto, may be performed by inducing a variation in the polynucleotide sequence via deletion, insertion, conservative substitution, non-conservative substitution, or a combination thereof so as to further enhance the activity of the expression regulation sequence; or by replacing the polynucleotide sequence with a polynucleotide sequence with a stronger activity. The expression regulation sequence, although not particularly limited thereto, may include a promoter, an operator sequence, a sequence encoding a ribosome-binding domain, and a sequence for regulating termination of transcription and translation, etc. Additionally, a strong exogenous promoter, instead of the original promoter, may be connected to the upper end of the expression unit of the polynucleotide.

Furthermore, the modification of the polynucleotide sequence on the chromosome, although not particularly limited thereto, may be performed by inducing a variation on the expression regulation sequence of the polynucleotide sequence via deletion, insertion, conservative substitution, non-conservative substitution, or a combination thereof so as to further enhance the activity of the polynucleotide sequence; or by replacing the polynucleotide sequence with an enhanced polynucleotide sequence with a stronger activity.

Generally, the introduction and enhancement of the protein activity may increase the activity or concentration of the corresponding protein relative to the activity or concentration of a wild-type protein or in a microorganism from at least 1%, 10%, 25%, 50%, 75%, 100%, 150%, 200%, 300%, 400%, or 500%, to a maximum of 1000% or 2000%.

Additionally, the microorganism may be one in which the activity of the endogenous homoserine *O*-succinyltransferase was attenuated or inactivated compared to that of the endogenous activity, in order to enhance the biosynthesis pathway of *O*-acetyl homoserine by blocking the pathway of biosynthesizing *O*-succinyl homoserine from homoserine.

The attenuation and inactivation of the homoserine *O*-succinyltransferase activity may be performed according to the method explained above.

In an exemplary embodiment of the present invention, the *O*-acetyl homoserine-producing microorganism may be one in which the activity of an enzyme involved

in the biosynthesis pathway from phosphoenolpyruvate to homoserine is additionally introduced or enhanced, in order to further increase the amount of homoserine, a substrate for the biosynthesis of *O*-acetyl homoserine.

Specifically, the above microorganism may be one, in which the activity of at least one protein selected from the group consisting of phosphoenolpyruvate carboxylase (*ppc*, EC 4.1.1.31), aspartate aminotransferase (*aspC*, EC 2.6.1.1), and aspartate semialdehyde dehydrogenase (*asd*, EC 1.2.1.11) is further introduced or enhanced.

For example, *ppc* gene encoding phosphoenolpyruvate carboxylate including an amino acid sequence represented by SEQ ID NO: 20, *aspC* gene encoding aspartate aminotransferase including an amino acid sequence represented by SEQ ID NO: 21, and *asd* gene encoding aspartate semialdehyde dehydrogenase including an amino acid represented by SEQ ID NO: 22 may be introduced into a microorganism. For example, the activities of the three different enzymes may be introduced and enhanced by making all the genes encoding the three different enzymes present in the chromosome of a host cell with a copy number of at least 2, but is not limited thereto. The introduction and enhancement of the activities may be performed according to the method described above.

In an exemplary embodiment of the present invention, the activity of citrate synthase protein was attenuated or inactivated by various methods, which includes deleting the citrate synthase gene in a microorganism of *E. coli* producing *O*-acetyl homoserine; introducing the gene encoding the modified citrate synthase protein, whose activity was attenuated compared to that of a wild-type, into the position of the citrate synthase gene; and introducing an expression vector for citrate synthase gene antisense RNA. As a result, the thus-constructed *O*-acetyl homoserine-producing microorganism, in which the activity of citrate synthase protein was attenuated or inactivated, showed an improved *O*-acetyl homoserine production capability, compared to that of the parent microorganism (Examples 1 to 4).

In another aspect, the present invention provides a method for producing *O*-acetyl homoserine using an *O*-acetyl homoserine-producing microorganism with an improved production capability of *O*-acetyl homoserine. Specifically, the present invention provides a method for producing *O*-acetyl homoserine including (a) culturing the microorganism; and (b) recovering *O*-acetyl homoserine produced during the cultivation of the microorganism.

The method of cultivation of the *E. coli* having *O*-acetyl homoserine production

capability according to the present invention may be performed according to the suitable media and culture conditions known in the art. The cultivation process may be easily adjusted by a skilled person in the art depending on the microorganism to be selected. In particular, since the microorganism of the present invention is a microorganism where the activity of the citrate synthase, which is an enzyme mediating the first step of the TCA cycle, is attenuated or inactivated, the cultivation medium may include glutamate, but is not specifically limited thereto.

Examples of the culture methods may include a batch culture, a continuous culture, and a fed-batch culture, but are not limited thereto. These various methods are, for example, disclosed in "Biochemical Engineering" by James M. Lee, Prentice-Hall International Editions, pp 138-176.

The medium used in the cultivation may appropriately meet the requirement of a specific microorganism. Specifically, examples of the microorganism culture media are disclosed in "Manual of Methods for General Bacteriology" by the American Society for Bacteriology, Washington, DC, 1981. The culture media may be those which include an appropriate carbon source, phosphorous source, inorganic compound, amino acid, and/or vitamins, etc, and cultivation may be performed in aerobic conditions while adjusting temperature, pH, etc.

Examples of the carbon source may include carbohydrates such as glucose, lactose, sucrose, lactic acid, fructose, maltose, starch, and cellulose; fats such as soybean oil, sunflower oil, castor oil, berber oil, and coconut oil; fatty acids such as palmitic acid, stearic acid, and linoleic acid; alcohols such as glycerol and ethanol; and organic acids such as acetic acid. These carbon sources may be used alone or in combination, but are not limited thereto.

Examples of the nitrogen source may include organic nitrogen sources such as peptone, yeast extract, gravy, malt extract, corn steep liquor (CSL), and bean flour; and inorganic nitrogen sources such as urea, ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate, and ammonium nitrate. These nitrogen sources may be used alone or in combination, but are not limited thereto. The culture media may further include, as a phosphorous source, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, and corresponding sodium-containing salts. The culture media may include metals such as magnesium sulfate and iron sulfate. Additionally, amino acids, vitamins and appropriate precursors may be included. These culture media or precursors may be added to the culture in the form of a batch culture or continuous culture, but are not limited thereto.

Additionally, the pH of the culture may be adjusted by adding a compound such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid, and sulfuric acid during

cultivation in an appropriate manner. Additionally, bubble formation may be prevented during the cultivation using an antifoaming agent such as fatty acid polyglycol ester. Additionally, in order to maintain aerobic conditions in a culture liquid, an oxygen gas or a gas (e.g., air) containing an oxygen gas may be added to a culture. The culture temperature may be from 20°C to 45°C, and specifically from 25°C to 40°C, but is not limited thereto. The cultivation may be continued until the production of *O*-acetyl homoserine reaches the intended level, and specifically for 10 hours to 160 hours, but is not limited thereto.

The method of producing *O*-acetyl homoserine of the present invention may further include recovering *O*-acetyl homoserine from the cultured microorganism or a cultured product thereof. The recovery of the intended *O*-acetyl homoserine may be performed by a microorganism cultivation method according to the present invention, for example, an appropriate method known in the art such as a batch culture, a continuous culture, and a fed-batch culture.

The recovery may include a purification step.

The thus-recovered *O*-acetyl homoserine can produce methionine by a two-step process (Korean Patent No. 10-0905381).

The two-step process includes a process of producing L-methionine and an organic acid by an enzyme reaction using an enzyme having the *O*-acetyl homoserine sulfhydrylase activity or a microorganism possessing the enzyme, while using the *O*-acetyl homoserine, which was produced by the L-methionine precursor-producing microorganism, and methyl mercaptan as substrates.

More specifically, the present invention provides a method for producing L-methionine by an enzyme reaction of *O*-acetyl homoserine sulfhydrylase, etc., using *O*-acetyl homoserine, which was accumulated by the above method, as a substrate.

In the second step, when *O*-acetyl homoserine is used as an L-methionine precursor, *O*-acetyl homoserine sulfhydrylase derived from a microorganism, specifically belonging to *Leptospira* sp., *Chromobacterium* sp., and *Hyphomonas* sp., and more specifically belonging to *Leptospira meyeri*, *Pseudomonas aurogenosa*, *Hyphomonas Neptunium*, and *Chromobacterium Violaceum* may be used.

The reaction is the same as shown below.



The additional process for producing methionine is disclosed in Korean Patent No. 10-0905381, and the entire specification of the patent may be included as a reference in the present invention.

MODE FOR INVENTION

Hereinafter, the present invention will be described in more detail with reference to the following Examples. However, these Examples are for illustrative purposes only, and the invention is not intended to be limited by these Examples.

Reference Example : Construction of O-acetyl homoserine-producing microorganism

<1-1> Deletion of *metB* gene derived from wild-type *E. coli* (International Publication No. WO 2008/013432)

An O-acetyl homoserine-producing microorganism was constructed using *E. coli*, a representative microorganism among *Escherichia* sp. To this end, wild-type *E. coli* K12 W3110 (ATCC27325) obtained from American Type Culture Collection (ATCC) was used. First, in order to block the synthesis pathway from O-succinyl-L-homoserine to cystathionine, cystathionine synthase-encoding *metB* gene (SEQ ID NO: 10) was deleted. Specifically, the cystathionine synthase-encoding *metB* gene was deleted via an FRT-one-step PCR deletion method (PNAS (2000) vol 97: P6640-6645).

Specifically, the *metB* deletion cassette was constructed via a PCR reaction based on the *pKD3* vector (PNAS (2000) vol 97: P6640-6645) as a template using primers of SEQ ID NOS: 30 and 31 as follows: 30 cycles of denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds, and extension at 72°C for 1 minute. The resulting PCR product was electrophoresed on a 1.0% agarose gel, and a 1.2 kb DNA band obtained therefrom was purified. The recovered DNA fragment was electroporated into *E. coli* (K12) W3110, which was already transformed with the *pKD46* vector (PNAS (2000) vol 97: P6640-6645). For electroporation, the W3110 strain transformed with the *pKD46* was cultured in an LB medium containing 100 µg/L ampicillin and 5 mM arabinose (L-arabinose) at 30°C until OD₆₀₀=0.6, and used after washing twice with sterile distilled water and once with 10% glycerol. Electroporation was performed at 2500 V. The recovered strain was streaked on an LB plate containing 25 µg/L chloramphenicol, cultured at 37°C overnight, and the strain showing resistance was selected. The selected strain was subjected to a PCR reaction under the same conditions based on the strain as a template

using the same primers, and the deletion of *metB* gene was confirmed by observing the gene size of 1.2 kb on a 1.0% agarose gel. The thus-confirmed strain was cultured in an LB medium after transforming again with the *pCP20* vector (PNAS (2000) vol 97: P6640-6645), and the final *metB* gene-deleted strain, where the gene size was reduced to 150 bp on a 1.0% agarose gel through PCR performed under the same conditions, was constructed and the removal of the chloramphenicol marker was confirmed. The thus-constructed strain was designated as “W3-B”.

<1-2> Deletion of *thrB* gene (International Publication No. WO 2008/013432)

In an effort to increase the amount of *O*-succinylhomoserine synthesis from homoserine, *thrB* gene, which is a homoserine kinase-encoding gene, was deleted. For deletion of the *thrB* gene from the W3-B strain constructed in Example 1, the FRT one step PCR deletion method used in the deletion of *metB* gene was used.

A *thrB* deletion cassette was constructed via PCR based on the *pKD4* vector (PNAS (2000) vol 97: P6640-6645) as a template using primers of SEQ ID NOS: 32 and 33 as follows: 30 cycles of denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds, and extension at 72°C for 1 minute.

The resulting PCR product was electrophoresed on a 1.0% agarose gel, and a 1.6 kb DNA band obtained therefrom was purified. The recovered DNA fragment was electroporated into W3-B strain, which was already transformed with the *pKD46* vector. The recovered strain was streaked on an LB plate containing 50 µg/L kanamycin, cultured at 37°C overnight, and the strain showing resistance was selected.

The selected strain was subjected to a PCR reaction under the same conditions directly based on the strain as a template using the same primers of SEQ ID NOS: 32 and 33, and confirmed the deletion of *thrB* gene by selecting the strain having the gene size of 1.6 kb on a 1.0% agarose gel. The thus-confirmed strain was cultured in an LB medium after transforming again with the *pCP20* vector, and the final *thrB* gene-deleted strain, where the gene size was reduced to 150 bp on a 1.0% agarose gel through PCR performed under the same conditions, was constructed and the removal of the kanamycin marker was confirmed. The thus-constructed strain was designated as “W3-BT”.

<1-3> A variant *metA* with homoserine acetyltransferase activity (International Publication No. WO 2012/087039)

In order to strengthen the homoserine acetyltransferase activity in the strain obtained in

Reference Example <1-2>, it was intended to introduce mutant type *metA* gene (SEQ ID NOS: 24 and 26) encoding homoserine acetyltransferase.

First, in order to construct the variant of *metA* gene with a strengthened activity, a PCR reaction was performed based on the chromosome of a wild-type strain *W3110* as a template using the primers of SEQ ID NOS: 34 and 35, and the *metA* gene encoding homoserine *O*-succinyltransferase was amplified.

The primers used in the PCR reaction were prepared based on the polynucleotide sequence of the *E. coli* chromosome, NC_000913, registered in the NIH Gene Bank, and the primers of SEQ ID NOS: 34 and 35 have the *EcoRV* and *HindIII* restriction sites, respectively. The thus-obtained PCR product and the *pCL1920* plasmid including *Pcj1* were respectively treated with *EcoRV* and *HindIII*, and the PCR product was cloned into the *pCL1920* plasmid. *E. coli* DH5 α was transformed using the cloned plasmid, and the transformed *E. coli* DH5 α was selected on LB plates containing 50 μ g/mL spectinomycin, and the plasmid was obtained therefrom. The thus-obtained plasmid was designated as “*pCL_Pcj1_metA*”.

Then, the 111th amino acid, glycine (Gly), of *O*-succinyltransferase was substituted with glutamic acid (Glu) (G111E) based on the above-constructed *pCL_Pcj1_metA* plasmid as a template using a site directed mutagenesis kit (Stratagene, USA). The thus-constructed plasmid including the variant of G111E *metA* gene was designated as “*pCL_Pcj1_metA* (EL)”.

Additionally, in order to substitute the 111th amino acid of *O*-succinyltransferase from glycine to glutamic acid, and the 112nd amino acid from leucine to histidine, primers of SEQ ID NOS: 38 and 39 were used. The plasmid including *metA* gene, in which the 111th amino acid was substituted from glycine to glutamic acid, and the 112nd amino acid was substituted from leucine to histidine was designated as “*pCL_Pcj1_metA* (EH)”.

Then, a replacement cassette, for the replacement with *metA* (EH) into a strain, was constructed via PCR using *pKD3* vector as a template along with primers of SEQ ID NOS: 40 and 41 as follows: 30 cycles of denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds, and extension at 72°C for 2 minutes. The respective PCR product was obtained using *pCL_Pcj1-metA* (EH) as a template for the *metA* (EH) part of the replacement cassette along with primers of SEQ ID NOS: 42 and 43, and primers of SEQ ID NOS: 42 and 45 for the wild-type *metA* part. *metA* (EH) replacement cassettes including the chloramphenicol marker part were constructed using the three different PCR products along with the primers of SEQ ID NOS: 42 and 45, and electroporated into *W3-BT* strain, which was already transformed with the *pKD46* vector, constructed in Reference Example <1-2>. The thus-confirmed strain was cultured in an LB medium after transforming again with the *pCP20* vector, and the strain, where the

chloramphenicol marker was removed, and *metA* gene was substituted with *metA* (EH) was designated as “W3-BTA”.

<1-4> Construction of a strain with 2 copies of *ppc*, *aspC*, and *asd* genes (European Patent Application Publication No. EP 2290051)

In order to increase the *O*-acetyl homoserine-producing capability of W3-BTA strain constructed in Reference Example <1-3>, the biosynthetic pathway was enhanced by citing the prior filed patent EP 2290051. In the same manner as in the above EP patent, a strain having 2 amplified copies each of the genes, i.e., the *ppc* gene encoding phosphoenolpyruvate carboxylase using primers of SEQ ID NOS: 46, 47, 48, and 49; the *aspC* gene encoding aspartate aminotransferase using primers of SEQ ID NOS: 50 and 51; and the *asd* gene encoding aspartate semialdehyde dehydrogenase using primers of SEQ ID NOS: 52, 53, 54, and 55, was constructed. In particular, the above strain with an enhanced biosynthetic pathway while producing *O*-acetyl homoserine was designated as “W3-BTA2PCD” (also called “WCJM”).

<1-5> Flask-culture Experiments

The amount of *O*-acetyl homoserine production by the strain constructed in Reference Examples <1-3> and <1-4> was tested by an Erlenmeyer flask-culture.

Specifically, W3110, W3-BTA, and WCJM strains were inoculated into LB media, and cultured at 33°C overnight. Then, a single colony thereof was inoculated into 3 mL of LB medium, cultured at 33°C for 5 hours, diluted 200-fold in a 250 mL Erlenmeyer flask containing 25 mL of an *O*-acetyl homoserine-producing medium, cultured at 33°C at a rate of 200 rpm for 30 hours, and the amount of *O*-acetyl homoserine production was examined via HPLC analysis. The media compositions used are shown in Table 1 below, and the amount of *O*-acetyl homoserine production examined is shown in Table 2 below.

[Table 1] Composition of *O*-acetyl homoserine-producing flask-culture

Composition	Conc. (per liter)
glucose	40 g
(NH ₄) ₂ SO ₄	17 g
KH ₂ PO ₄	1.0 g
MgSO ₄ · 7H ₂ O	0.5 g
FeSO ₄ · 7H ₂ O	5 mg

MnSO ₄ · 8H ₂ O	5 mg
ZnSO ₄	5 mg
CaCO ₃	30 g
yeast extract	2 g
methionine	0.15 g
threonine	0.15 g

[Table 2]

	OD (562nm)	Glucose consumption (g/L)	O-Acetyl homoserine (g/L)
<i>W3110</i>	14.2	40	0
<i>W3-BTA</i>	8.4	36	0.9
<i>WCJM</i>	9.6	35	1.2

The result revealed that the wild-type *W3110* did not produce *O*-acetyl homoserine at all, whereas the *W3-BTA* strain produced 0.9 g/L of *O*-acetyl homoserine and the *WCJM* strain, which was strengthened with the biosynthesis pathway, produced 1.2 g/L of *O*-acetyl homoserine.

Example 1: Deletion of citrate synthase activity

<1-1> Construction of a citrate synthase gene-deleted microorganism in an *O*-acetyl homoserine-producing microorganism

Citrate synthase (GltA) is the enzyme in the first step of the TCA cycle, and starts with the reaction between oxaloacetate and acetyl-CoA. The growth inhibition by decrease in the TCA cycle is well known (Meded Rijksuniv Gent Fak Landbouwkde Toegep Biol Wet. 2001; 66(3a): 333-6). However, in order to increase the amount of acetyl-CoA used as a substrate for *O*-acetyl homoserine, *W3-BTA* and *WCJM* strains where citrate synthase activity is deleted were to be produced.

Specifically, the citrate synthase gene in *W3-BTA* and *WCJM* strains was deleted via PCR based on *pKD4* vector as a template using primers of SEQ ID NOS: 56 and 57 as follows: 30 cycles of denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds, and extension at 72°C for 2 minutes. The resulting PCR product was electrophoresed on a 1.0% agarose gel,

and the size of the gene was confirmed to be 1.6 kb, and its DNA was purified. The recovered DNA fragments were electroporated into *W3-BTA* and *WCJM* strains, which were already transformed with the *pKD46* vector. For electroporation, *W3-BTA* and *WCJM* strains, transformed with the *pKD46* vector, were cultured in an LB medium containing 100 µg/L ampicillin and 5 mM arabinose at 30°C until OD₆₀₀=0.6, and washed twice with distilled water and once with 10% glycerol to be used. Electroporation was performed at 2500 V. The thus-recovered strains were streaked on LB plates containing 50 µg/L kanamycin, cultured at 37°C, and the strains showing resistance were selected.

The selected strains were subjected to PCR using the primers of SEQ ID NOS: 58 and 59 under the same conditions, electrophoresed on a 1.0% agarose gel, and the size of the gene was observed to be 2.5 kb, thereby confirming that a deletion cassette was inserted into the citrate synthase gene portion on the chromosome. The thus-confirmed strains were transformed again with the *pCP20* vector, cultured in LB media, and strains having a deletion of the citrate synthase gene, whose size was reduced to 1.1 kb on a 1.0% agarose gel, were constructed by PCR, and it was confirmed that kanamycin markers were removed. The thus-constructed strains were designated as “*W3-BTA-AD*” and “*WCJM-AD*”, respectively.

<1-2> Evaluation of a citrate synthase gene-deleted microorganism in an *O*-acetyl homoserine-producing microorganism

W3-BTA-AD and *WCJM-AD* strains can grow in an LB medium, but due to the deletion of the citrate synthase gene, they could not grow in an *O*-acetyl homoserine-containing medium. In order to test the amount of *O*-acetyl homoserine production, an Erlenmeyer flask-culture was performed under the condition (Table 3 – a composition adding glutamate in the medium) of adding 3 g/L of glutamate into the existing composition of the culture medium.

Specifically, *W3-BTA-AD* and *WCJM-AD* strains were inoculated into LB media and cultured at 33°C overnight. Then, a single colony thereof was inoculated into 3 mL of LB medium, cultured at 33°C for 5 hours, diluted 200-fold in a 250 mL Erlenmeyer flask containing 25 mL of an *O*-acetyl homoserine-producing medium (with glutamate added), cultured at 33°C at a rate of 200 rpm for 30 hours, and the amount of *O*-acetyl homoserine production was examined via HPLC analysis. The amount of *O*-acetyl homoserine production examined is shown in Table 4 below.

[Table 3] Composition of a medium with glutamate added to a basal medium

Composition	Conc. (per liter)
glucose	40 g
(NH ₄) ₂ SO ₄	17 g
KH ₂ PO ₄	1.0 g
MgSO ₄ · 7H ₂ O	0.5 g
FeSO ₄ · 7H ₂ O	5 mg
MnSO ₄ · 8H ₂ O	5 mg
ZnSO ₄	5 mg
CaCO ₃	30 g
yeast extract	2 g
methionine	0.15 g
threonine	0.15 g
glutamate	3 g

[Table 4] Production of *O*-acetyl homoserine via flask-culture

	OD (562 nm)	Glucose consumption (g/L)	<i>O</i>-acetyl homoserine (g/L)	Glutamate (g/L)
<i>W3-BTA</i>	9.9	38	0.9	3.2
<i>W3-BTA-AD</i>	6.1	34	1.4	2.3
<i>WCJM</i>	9.2	37	1.3	3.5
<i>WCJM-AD</i>	5.6	33	2.1	1.7

The result of the *O*-acetyl homoserine production via flask-culture revealed that the *W3-BTA* strain produced 0.9 g/L of *O*-acetyl homoserine, and *W3-BTA-AD* produced 1.4 g/L of *O*-acetyl homoserine, which is a 55.6% increase, although it showed a decrease in its glucose consumption. The *WCJM* strain produced 1.3 g/L of *O*-acetyl homoserine while the *WCJM-AD* strain produced 2.1 g/L of *O*-acetyl homoserine, thus confirming that the *O*-acetyl homoserine production capability was improved by 61.5% due to the deletion of the citrate synthase gene.

Example 2: Attenuation of the activity of citrate synthase protein

<2-1> Kinds of citrate synthase gene modifications

The *WCJM*-AD strain constructed in Example <1-1> showed a low culture rate, and three different types of variants, which showed an attenuated activity and a reduced binding ability to acetyl-CoA according to various modificationss of citrate synthase known in numerous references (The Journal of Biological Chemistry, 2003, 278, 35435-35443), were selected. The information on the three different types of variants is shown in Table 5, which shows modified genes in which the 145th amino acid, tyrosine (Y), was substituted with alanine (A), and the 167th amino acid, lysine(K), was substituted with alanine (A), and the 204th amino acid, threonine (T), was substituted with alanine (A).

[Table 5]

Evaluation on citrate synthase (gltA) variants

	KM VALUE [mM]	
	Acetyl-CoA	OAA
WT	0.12	0.026
Y145A	0.23	0.051
K167A	0.22	0.037
T204A	0.21	0.004

<2-2> Construction of a microorganism with attenuated citrate synthase protein activity in an O-acetyl homoserine-producing microorganism

The present inventors intended to increase the production capability by introducing the variants, in which the activity of citrate synthase protein was attenuated as explained in Example <2-1>, into the *O*-acetyl homoserine-producing microorganism.

In order to introduce the three different types of citrate synthase gene variants into the *WCJM*-AD strain, a modification replacement cassette was designed as shown in FIG. 1. Each variant was synthesized by substituting a primer with a nucleotide, and each cassette was constructed through 3 PCR products. For the citrate synthase gene portion, the *W3110* strain was used as a template, and the modification on the 145th amino acid produced PCR reactions were performed using the primers of SEQ ID NOS: 60 and 63 and SEQ ID NOS: 62 and 61, respectively, and obtained PCR products with a size of 514 bp and 1,112 bp.

Likewise, the modification on the 167th amino acid produced PCR products with a size of 580 bp and 1,046 bp using the primers of SEQ ID NOS: 60 and 65, and the primers of SEQ ID

NOS: 64 and 61, and the modification on the 204th amino acid produced PCR products with a size of 688 bp and 936 bp using the primers of SEQ ID NOS: 60 and 67 and SEQ ID NOS: 66 and 61. For the common kanamycin portion, PCR reactions were performed based on the *pKD4* vector as a template using the primers of SEQ ID NOS: 68 and 69. In particular, for the insertion into the position of the citrate synthase gene, the cassette was constructed so as to include the polynucleotide sequence downstream of the citrate synthase gene in the SEQ ID NO: 69, and a PCR product with a size of 1,571 bp was obtained via electrophoresis. A sewing PCR reaction was performed based on the kanamycin DNA fragment, which is the common part with each of the two DNA fragments collected according to the modifications, respectively, using the primers of SEQ ID NOS: 60 and 69, as follows: 30 cycles of denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds, and extension at 72°C for 4 minutes. Each of the final PCR products was confirmed on a 1.0% agarose gel, and the DNA fragments with a size of 3,115 bp for the three different kinds of cassettes of citrate synthase gene modifications. The collected DNA fragments were electroporated into the *WCJM-AD* strain, which was already transformed with the *pKD46* vector. For electroporation, the *W3110* strain transformed with the *pKD46* was cultured in an LB medium containing 100 µg/L ampicillin and 5 mM arabinose at 30°C until OD₆₀₀=0.6, and used after washing twice with sterile distilled water and once with 10% glycerol. Electroporation was performed at 2500 V. The recovered strain was streaked on an LB plate containing 25 µg/L kanamycin, cultured at 37°C overnight, and the strain showing resistance was selected. The selected strain was subjected to a PCR reaction under the same conditions based on the strain as a template using the same primers of SEQ ID NOS: 58 and 59, and confirmed the deletion of *metB* gene by observing the gene size of 3.7 kb on a 1.0% agarose gel, thereby confirming that a modification cassette, in which the amino acid of the citrate synthase gene was substituted, was inserted. The thus-confirmed strain was cultured in an LB medium after transforming again with the *pCP20* vector, and the three variant strains regarding the citrate synthase activity, where the gene size was reduced to 2.5 kb on a 1.0% agarose gel through PCR performed under the same conditions, were constructed and the removal of the kanamycin marker was confirmed. The thus-constructed strains were designated as “*WCJM-A145*”, “*WCJM-A167*”, and “*WCJM-A204*”, and the sequence information of the citrate synthase gene introduced with modifications are shown in SEQ ID NOS: 1 to 3 (amino acid sequences) and SEQ ID NOS: 5 to 7 (nucleotide sequences), respectively.

<2-3> Evaluation of microorganisms with attenuated citrate synthase activity in O-acetyl homoserine-producing microorganisms

An Erlenmeyer flask-culture was performed in order to examine the amount of *O*-acetyl homoserine production by three different strains of *WCJM-A145*, *WCJM-A167*, and *WCJM-A204*, in which the activity of the citrate synthase gene was attenuated. Four kinds of strains, i.e., *WCJM-A145*, *WCJM-A167*, and *WCJM-A204* strains including the *WCJM* strain, were inoculated into LB media, and cultured at 33°C overnight. Then, a single colony thereof was inoculated into 3 mL of LB medium, cultured at 33°C for 5 hours, diluted 200-fold in a 250 mL Erlenmeyer flask containing 25 mL of an *O*-acetyl homoserine-producing medium, cultured at 33°C at a rate of 200 rpm for 30 hours, and the amount of *O*-acetyl homoserine production was examined via HPLC analysis. The results are shown in Table 6 below.

[Table 6] Production of *O*-acetyl homoserine via flask-culture

	OD (562 nm)	Glucose consumption (g/L)	<i>O</i>-acetyl homoserine (g/L)	Glutamate (g/L)
<i>WCJM</i>	8.9	35	1.3	1.3
<i>WCJM-A145</i>	7.4	35	2.0	0
<i>WCJM-A167</i>	6.3	29	1.9	0
<i>WCJM-A204</i>	9.1	40	1.1	1.8

The result of *O*-acetyl homoserine production via flask-culture revealed that the *WCJM* strain produced 1.3 g/L of *O*-acetyl homoserine, and the two strains, *WCJM-A145* and *WCJM-A167*, produced 2.0 g/L and 1.9 g/L of *O*-acetyl homoserine, respectively, while the amount of their glucose consumption decreased along with the decrease in their absorbance (OD). Considering the specific decrease of glutamate from 1.3 g/L to 0 g/L, it was confirmed that the result is due to the decrease in TCA cycle flow caused by the attenuation in the citrate synthase activity. However, the *WCJM-A204* strain showed an increase in glutamate while showing a decrease in the amount of *O*-acetyl homoserine production to 0.2 g/L, thus confirming the modification is one with a strengthened activity.

Example 3: Attenuation in expression of citrate synthase protein

<3-1> Construction of expression vector for citrate synthase gene antisense RNA (asRNA)

The present inventors made an effort to apply an antisense RNA (asRNA) technology in

order to attenuate the expression of citrate synthase protein. The antisense RNA technology is a method for reducing protein expression by neutralizing the binding between citrate synthase mRNA and ribosome, via overexpression of the complementary binding portion to the citrate synthase mRNA of the target gene. This method has the advantage in that it can regulate the level of inhibition by controlling the binding force with the mRNA of the citrate synthase gene, and this method is also useful for the construction of a recombinant microorganism because this method can effectively construct and reduce gene expression via antisense RNA controlling gene expression, not necessitating the conventional process of gene deletion.

The vector construction was performed referring to a reference (Methods Mol Biol. 2012; 815:307-19. doi: 10.1007/978-1-61779-424-7_23.), and for overexpression, the antisense RNA region of the synthase gene was to be introduced into the *pBAD24* plasmid capable of induction. The *pBAD24*-citrate synthase asRNA vector map is shown in FIG. 2. The region where the antisense RNA of the citrate synthase gene was expressed has a size of 100 bp including the 52 bp region of the promoter region and the 48 bp region from the initiation codon of the citrate synthase, and a 38 bp paired termini (PT) structure, which reduces the instability of the antisense RNA (asRNA), is connected to both flanking regions. The antisense RNA region of the citrate synthase gene was obtained using the primers of SEQ ID NOS: 70 and 71, and the *NcoI* and *HindIII* restriction sites were included to be cloned into a vector.

The thus-obtained PCR product had a size of 194 bp, and the PCR product was cloned into the *pBAD24* plasmid after treating them with *EcoRV* and *HindIII*, respectively. The thus-cloned plasmid was used to transform *E. coli* DH5 α , and the transformed *E. coli* DH5 α was selected from the LB plates containing 100 μ g/mL of ampicillin, and obtained the plasmid therefrom. The thus-obtained plasmid was designated as “*pBAD24-gltA* asRNA”.

<3-2> Introduction of an expression vector of antisense RNA of citrate synthase gene into an *O*-acetyl homoserine-producing microorganism and evaluation thereof

The *pBAD24-gltA*-asRNA, an expression vector of antisense RNA of citrate synthase gene, was transformed into the *WCJM* strain, which is an *O*-acetyl homoserine-producing microorganism. Here, the transformed strain was designated as “*WCJM/A*-asRNA”. In particular, it was attempted to control the expression amount of the citrate synthase protein by controlling the expression amount of the antisense RNA of the citrate synthase, and here, the expression amount of the antisense RNA can be controlled according to the concentration of arabinose.

As a result, it was confirmed that the amount of the *O*-acetyl homoserine production

increased when the activity of the citrate synthase was attenuated as in Example 2.

Additionally, an Erlenmeyer flask-culture was performed to examine whether the amount of *O*-acetyl homoserine production increases as the expression amount of the citrate synthase decreases.

Specifically, *WCJM* and *WCJM/A-asRNA* strains were inoculated into LB media, and cultured at 33°C overnight. Then, a single colony thereof was inoculated into 3 mL of LB medium, cultured at 33°C for 5 hours, diluted 200-fold in a 250 mL Erlenmeyer flask containing 25 mL of an *O*-acetyl homoserine-producing medium. In particular, in order to control the expression amount of antisense RNA of the citrate synthase, arabinose was added at concentrations of 0 mM, 2 mM, and 5 mM, and cultured at 33°C at a rate of 200 rpm for 15 hours and 30 hours. The amount of *O*-acetyl homoserine production was examined via HPLC analysis, and the results are shown in Tables 7 and 8 below.

[Table 7]

15 Hours	Arabinose	OD (562nm)	Glucose consumption (g/L)	<i>O</i>-acetyl homoserine (g/L)
<i>WCJM</i>	0 mM	4.2	9.7	0.5
<i>WCJM</i>	2 mM	4.5	8.9	0.6
<i>WCJM</i>	5 mM	4.7	8.9	0.5
<i>WCJM/A-asRNA</i>	0 mM	4.5	10.1	0.6
<i>WCJM/A-asRNA</i>	2 mM	4.2	8.8	0.6
<i>WCJM/A-asRNA</i>	5 mM	3.4	6.9	0.5

[Table 8]

30 Hours	Arabinose	OD (562nm)	Glucose consumption (g/L)	<i>O</i>-acetyl homoserine (g/L)
<i>WCJM</i>	0 mM	8.9	32	1.4
<i>WCJM</i>	2 mM	9.1	34	1.3

<i>WCJM</i>	5 mM	8.9	33	1.3
<i>WCJM/A-asRNA</i>	0 mM	9.2	33	1.3
<i>WCJM/A-asRNA</i>	2 mM	8.8	32	1.6
<i>WCJM/A-asRNA</i>	5 mM	7.1	29	1.7

As a result, it was confirmed that, when cultured for 15 hours, the *WCJM/A-asRNA* strain showed a decrease in OD by about 1 according to the concentration of arabinose, whereas the concentration of *O*-acetyl homoserine was similar. However, when cultured for 30 hours, the *WCJM* strain, which is a control strain, showed the same OD and *O*-acetyl homoserine concentration even when the concentration of arabinose increased, whereas the *WCJM/A-asRNA* strain, which is a strain introduced with the expression vector for citrate synthase RNA antisense, showed a marked difference as the concentration of arabinose increased. The OD was 9.2 when the arabinose concentration was 0 mM, whereas the OD was 7.1 at 5 mM of the arabinose concentration, a decrease of 5.1, and the amount of *O*-acetyl homoserine increased by 30.8% although the glucose consumption was small. From these results, it was confirmed that not only the attenuation in citrate synthase activity but also in the attenuation in protein expression exhibit the same results.

Example 4: Attenuation and inactivation of citrate synthase activity in a microorganism with high production yield of *O*-acetyl homoserine

<4-1> Construction of a microorganism with high *O*-acetyl homoserine production yield with inactivated citrate synthase activity and evaluation thereof

International Publication No. WO 2012/087039 discloses in detail a method for constructing an *O*-acetyl homoserine-producing microorganism from a threonine-producing microorganism derived from a wild-type *W3110* strain, due to NTG mutation. In particular, the constructed strain producing *O*-acetyl homoserine with high yield was deposited at Korean Culture Center of Microorganisms (KCCM) under the Accession No of *KCCM 11146P*.

The *KCCM11146P* strain can consume 40 g/L of glucose during a flask-culture and produces about 15 g/L to 16 g/L of *O*-acetyl homoserine and is thus regarded as having high

O-acetyl homoserine production capability. Accordingly, in order to examine whether the strain produces a higher yield of *O*-acetyl homoserine when the citrate synthase activity is deleted, the same was applied to the *KCCM11146P* strain. The construction method was the same as in Example <1-1>, and by this method, the *KCCM11146P* strain, where the citrate synthase activity was deleted, was constructed and designated as “*KCCM11146P-AD*”.

The amount of *O*-acetyl homoserine production by the *KCCM11146P* strain, where the citrate synthase activity was deleted, was tested by an Erlenmeyer flask-culture. The *KCCM11146P* or *KCCM11146P-AD* strain was inoculated into an LB medium and cultured at 33°C overnight. Then, a single colony thereof was inoculated into 3 mL of LB medium, cultured at 33°C for 5 hours, diluted 200-fold in a 250 mL Erlenmeyer flask containing 25 mL of an *O*-acetyl homoserine-producing medium (with glutamate added), and cultured at 33°C at a rate of 200 rpm for 30 hours. The amount of *O*-acetyl homoserine production was examined via HPLC analysis, and the results are shown in Table 9 below.

[Table 9] Production of *O*-acetyl homoserine via flask-culture

	OD (562nm)	Glucose consumption (g/L)	<i>O</i> -acetyl homoserine (g/L)	Glutamate (g/L)
<i>KCCM11146P</i>	18.3	60	14.2	4.6
<i>KCCM11146P-AD</i>	14.6	60	16.7	1.8

The result of *O*-acetyl homoserine production via flask-culture revealed that the *KCCM11146P* strain produced 14.2 g/L of *O*-acetyl homoserine, and the *KCCM11146P-AD* strain produced 16.7 g/L of *O*-acetyl homoserine, a 17.6% increase, although it showed a decrease in absorbance (OD).

<4-2> Construction of a microorganism with high *O*-acetyl homoserine production yield with attenuated citrate synthase activity and evaluation thereof

In order to examine whether the *KCCM11146P* strain, which is a strain with high production yield of *O*-acetyl homoserine, produces a higher yield of *O*-acetyl homoserine even when the citrate synthase activity is attenuated, the modification on the 145th amino acid (from tyrosine (Y) to alanine (A)) and the modification on the 167th amino acid (from lysine (K) to alanine (A)), which showed the highest *O*-acetyl homoserine-producing capabilities among the three variant types attenuating the protein activities explained in Example <2-1>, were applied to

the *KCCM11146P* strain.

The construction method was the same as in Example <2-2>, and by the method, two *KCCM11146P* strains, where the citrate synthase activity was attenuated, were constructed and designated as “*KCCM11146P*-A145” and “*KCCM11146P*-A167”, respectively.

The amount of *O*-acetyl homoserine production by the two strains of *KCCM11146P*-A145 and *KCCM11146P*-A167, where the citrate synthase activity was attenuated, was tested by an Erlenmeyer flask-culture. The three strains, i.e., *KCCM11146P*-A145 and *KCCM11146P*-A167 strains and the *KCCM11146P* strain, were inoculated into LB media, and cultured at 33°C overnight. Then, a single colony thereof was inoculated into 3 mL of LB medium, cultured at 33°C for 5 hours, diluted 200-fold in a 250 mL Erlenmeyer flask containing 25 mL of an *O*-acetyl homoserine-producing medium, and cultured at 33°C at a rate of 200 rpm for 30 hours. The amount of *O*-acetyl homoserine production was examined via HPLC analysis, and the results are shown in Table 10 below.

[Table 10] Production of *O*-acetyl homoserine via flask-culture

	OD (562nm)	Glucose consumption (g/L)	<i>O</i>-acetyl homoserine (g/L)	Glutamate (g/L)
<i>KCCM11146P</i>	16.3	60	15.0	1.6
<i>KCCM11146P</i> -A145	14.6	60	17.5	0
<i>KCCM11146P</i> -A167	14.2	60	17.3	0

The result of *O*-acetyl homoserine production via flask-culture revealed that the *KCCM11146P* strain produced 15.0 g/L of *O*-acetyl homoserine, and the two strains of *KCCM11146P*-A145 and *KCCM11146P*-A167 showed similar results as in Example <2-3>. The two strains respectively produced 17.5 g/L and 17.3 g/L of *O*-acetyl homoserine, an increase of about 16.7%, although they both showed a decrease in absorbance (OD).

The strain with high production yield of *O*-acetyl homoserine also showed a decrease in glutamate from 1.6 g/L to 0 g/L, according to the decrease in TCA cycle flow caused by the attenuation in the citrate synthase activity.

These results demonstrate that citrate synthase activity enables production of *O*-acetyl

homoserine by applying the attenuated modification. Additionally, they also indicate that when a conversion reaction is conducted based on the *O*-acetyl homoserine, which was produced according to the International Publication No. WO2008/013432, as a template, and using a conversion enzyme, which additionally has the activities of cystathionine gamma synthase, *O*-succinylhomoserine sulfhydrylase, and *O*-acetyl homoserine sulfhydrylase, it is possible to simultaneously synthesize L-methionine and acetate.

The present inventors confirmed that the *KCCM11146P* strain, the variant on the 167th amino acid of the citrate synthase, has an improved production of *O*-acetyl homoserine, designated the *KCCM11146P-A167* strain as “CA05-4007”, and deposited it at the Korean Culture Center of Microorganisms (KCCM), an international depositary authority under the Budapest Treaty, on Nov. 22, 2013 (Accession No: *KCCM 11483P*).

From the foregoing, a skilled person in the art to which the present invention pertains will be able to understand that the present invention may be embodied in other specific forms without modifying the technical concepts or essential characteristics of the present invention. In this regard, the exemplary embodiments disclosed herein are only for illustrative purposes and should not be construed as limiting the scope of the present invention. On the contrary, the present invention is intended to cover not only the exemplary embodiments but also various alternatives, modifications, equivalents and other embodiments that may be included within the spirit and scope of the present invention as defined by the appended claims.



BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

To. CJ CheilJedang Corporation
CJ CHEILJEDANG CENTER,
330, DONGHO-RO,
JUNG-GU, SEOUL 100-400,
REPUBLIC OF KOREA

RECEIPT IN THE CASE OF AN ORIGINAL
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR : <i>Escherichia coli</i> CA05-4007	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: KCCM11483P
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I above was accompanied by: ☐ a scientific description ☐ a proposed taxonomic designation (Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on November. 22. 2013. (date of the original deposit) ¹	
IV. INTERNATIONAL DEPOSITARY AUTHORITY	
Name : Korean Culture Center of Microorganisms Address : Yurim B/D 45, Hongjena-e-2ga-gil Seodaemun-gu SEOUL 120-861 Republic of Korea	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s) : Date: November. 22. 2013.

¹ Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired; where a deposit made outside the Budapest Treaty after the acquisition of the status of international depositary authority is converted into a deposit under the Budapest Treaty, such date is the date on which the microorganism was received by the international depositary authority.

Form BP/4

Sole page

한국미생물보존센터

120-027 서울서초동우암로 361-221 유원빌딩 Tel: 02-391-0950, 396-9950 Fax: 02-392-0855 E-mail: kccm@kccm.or.kr

KOREAN CULTURE CENTER OF MICROORGANISMS

Yopam Bldg. 361-221 Hongje-dong, Seodaemun-gu, Seoul, 120-0191, Korea Tel: 82-2-391-0950, 396-9950 Fax: 82-2-392-0859 E-mail: kccm@kccm.or.kr

Sequence Listings

<110> CJ CheilJedang Corporation

<120> Microorganism producing O-acetyl homoserine and the method of
producing O-acetyl homoserine using the same

<130> OPA15136

<150> KR 10-2014-0076779

<151> 2014-06-23

<160> 71

<170> KopatentIn 2.0

<210> 1

<211> 427

<212> PRT

<213> Artificial Sequence

<220>

<223> GltA A145

<400> 1

Met Ala Asp Thr Lys Ala Lys Leu Thr Leu Asn Gly Asp Thr Ala Val

1 5 10 15

Glu Leu Asp Val Leu Lys Gly Thr Leu Gly Gln Asp Val Ile Asp Ile

20 25 30

Arg Thr Leu Gly Ser Lys Gly Val Phe Thr Phe Asp Pro Gly Phe Thr

35 40 45

Ser Thr Ala Ser Cys Glu Ser Lys Ile Thr Phe Ile Asp Gly Asp Glu

50 55 60

Gly Ile Leu Leu His Arg Gly Phe Pro Ile Asp Gln Leu Ala Thr Asp

65 70 75 80

Ser Asn Tyr Leu Glu Val Cys Tyr Ile Leu Leu Asn Gly Glu Lys Pro

85 90 95

Thr Gln Glu Gln Tyr Asp Glu Phe Lys Thr Thr Val Thr Arg His Thr

100 105 110

Met Ile His Glu Gln Ile Thr Arg Leu Phe His Ala Phe Arg Arg Asp

115 120 125

Ser His Pro Met Ala Val Met Cys Gly Ile Thr Gly Ala Leu Ala Ala

130 135 140

Phe Ala His Asp Ser Leu Asp Val Asn Asn Pro Arg His Arg Glu Ile

145 150 155 160

Ala Ala Phe Arg Leu Leu Ser Lys Met Pro Thr Met Ala Ala Met Cys

165 170 175

Tyr Lys Tyr Ser Ile Gly Gln Pro Phe Val Tyr Pro Arg Asn Asp Leu

180 185 190

Ser Tyr Ala Gly Asn Phe Leu Asn Met Met Phe Ser Thr Pro Cys Glu

195 200 205

Pro Tyr Glu Val Asn Pro Ile Leu Glu Arg Ala Met Asp Arg Ile Leu

210 215 220

Ile Leu His Ala Asp His Glu Gln Asn Ala Ser Thr Ser Thr Val Arg

225 230 235 240

Thr Ala Gly Ser Ser Gly Ala Asn Pro Phe Ala Cys Ile Ala Ala Gly

245 250 255

Ile Ala Ser Leu Trp Gly Pro Ala His Gly Gly Ala Asn Glu Ala Ala

260 265 270

Leu Lys Met Leu Glu Glu Ile Ser Ser Val Lys His Ile Pro Glu Phe

275 280 285

Val Arg Arg Ala Lys Asp Lys Asn Asp Ser Phe Arg Leu Met Gly Phe

290 295 300

Gly His Arg Val Tyr Lys Asn Tyr Asp Pro Arg Ala Thr Val Met Arg

305 310 315 320

Glu Thr Cys His Glu Val Leu Lys Glu Leu Gly Thr Lys Asp Asp Leu

325 330 335

Leu Glu Val Ala Met Glu Leu Glu Asn Ile Ala Leu Asn Asp Pro Tyr

340 345 350

Phe Ile Glu Lys Lys Leu Tyr Pro Asn Val Asp Phe Tyr Ser Gly Ile

355 360 365

Ile Leu Lys Ala Met Gly Ile Pro Ser Ser Met Phe Thr Val Ile Phe

370 375 380

Ala Met Ala Arg Thr Val Gly Trp Ile Ala His Trp Ser Glu Met His

385 390 395 400

Ser Asp Gly Met Lys Ile Ala Arg Pro Arg Gln Leu Tyr Thr Gly Tyr

405 410 415

Glu Lys Arg Asp Phe Lys Ser Asp Ile Lys Arg

420 425

<210> 2

<211> 427

<212> PRT

<213> Artificial Sequence

<220>

<223> GltA A167

<400> 2

Met Ala Asp Thr Lys Ala Lys Leu Thr Leu Asn Gly Asp Thr Ala Val

1 5 10 15

Glu Leu Asp Val Leu Lys Gly Thr Leu Gly Gln Asp Val Ile Asp Ile

20 25 30

Arg Thr Leu Gly Ser Lys Gly Val Phe Thr Phe Asp Pro Gly Phe Thr

35 40 45

Ser Thr Ala Ser Cys Glu Ser Lys Ile Thr Phe Ile Asp Gly Asp Glu

50 55 60

Gly Ile Leu Leu His Arg Gly Phe Pro Ile Asp Gln Leu Ala Thr Asp

65 70 75 80

Ser Asn Tyr Leu Glu Val Cys Tyr Ile Leu Leu Asn Gly Glu Lys Pro

85 90 95

Thr Gln Glu Gln Tyr Asp Glu Phe Lys Thr Thr Val Thr Arg His Thr

100 105 110

Met Ile His Glu Gln Ile Thr Arg Leu Phe His Ala Phe Arg Arg Asp

115 120 125

Ser His Pro Met Ala Val Met Cys Gly Ile Thr Gly Ala Leu Ala Ala

130 135 140

Phe Tyr His Asp Ser Leu Asp Val Asn Asn Pro Arg His Arg Glu Ile

145 150 155 160

Ala Ala Phe Arg Leu Leu Ser Ala Met Pro Thr Met Ala Ala Met Cys

165 170 175

Tyr Lys Tyr Ser Ile Gly Gln Pro Phe Val Tyr Pro Arg Asn Asp Leu

180 185 190

Ser Tyr Ala Gly Asn Phe Leu Asn Met Met Phe Ser Thr Pro Cys Glu

195 200 205

Pro Tyr Glu Val Asn Pro Ile Leu Glu Arg Ala Met Asp Arg Ile Leu

210 215 220

Ile Leu His Ala Asp His Glu Gln Asn Ala Ser Thr Ser Thr Val Arg

225 230 235 240

Thr Ala Gly Ser Ser Gly Ala Asn Pro Phe Ala Cys Ile Ala Ala Gly

245 250 255

Ile Ala Ser Leu Trp Gly Pro Ala His Gly Gly Ala Asn Glu Ala Ala

260 265 270

Leu Lys Met Leu Glu Glu Ile Ser Ser Val Lys His Ile Pro Glu Phe

275 280 285

Val Arg Arg Ala Lys Asp Lys Asn Asp Ser Phe Arg Leu Met Gly Phe

290 295 300

Gly His Arg Val Tyr Lys Asn Tyr Asp Pro Arg Ala Thr Val Met Arg

305 310 315 320

Glu Thr Cys His Glu Val Leu Lys Glu Leu Gly Thr Lys Asp Asp Leu

325 330 335

Leu Glu Val Ala Met Glu Leu Glu Asn Ile Ala Leu Asn Asp Pro Tyr

340 345 350

Phe Ile Glu Lys Lys Leu Tyr Pro Asn Val Asp Phe Tyr Ser Gly Ile

355 360 365

Ile Leu Lys Ala Met Gly Ile Pro Ser Ser Met Phe Thr Val Ile Phe

370 375 380

Ala Met Ala Arg Thr Val Gly Trp Ile Ala His Trp Ser Glu Met His

385 390 395 400

Ser Asp Gly Met Lys Ile Ala Arg Pro Arg Gln Leu Tyr Thr Gly Tyr

405 410 415

Glu Lys Arg Asp Phe Lys Ser Asp Ile Lys Arg

420 425

<210> 3

<211> 427

<212> PRT

<213> Artificial Sequence

<220>

<223> GltA A204

<400> 3

Met Ala Asp Thr Lys Ala Lys Leu Thr Leu Asn Gly Asp Thr Ala Val

1 5 10 15

Glu Leu Asp Val Leu Lys Gly Thr Leu Gly Gln Asp Val Ile Asp Ile

20 25 30

Arg Thr Leu Gly Ser Lys Gly Val Phe Thr Phe Asp Pro Gly Phe Thr

35 40 45

Ser Thr Ala Ser Cys Glu Ser Lys Ile Thr Phe Ile Asp Gly Asp Glu

50 55 60

Gly Ile Leu Leu His Arg Gly Phe Pro Ile Asp Gln Leu Ala Thr Asp

65 70 75 80

Ser Asn Tyr Leu Glu Val Cys Tyr Ile Leu Leu Asn Gly Glu Lys Pro

85 90 95

Thr Gln Glu Gln Tyr Asp Glu Phe Lys Thr Thr Val Thr Arg His Thr

100 105 110

Met Ile His Glu Gln Ile Thr Arg Leu Phe His Ala Phe Arg Arg Asp

115 120 125

Ser His Pro Met Ala Val Met Cys Gly Ile Thr Gly Ala Leu Ala Ala

130 135 140

Phe Tyr His Asp Ser Leu Asp Val Asn Asn Pro Arg His Arg Glu Ile

145 150 155 160

Ala Ala Phe Arg Leu Leu Ser Lys Met Pro Thr Met Ala Ala Met Cys

165 170 175

Tyr Lys Tyr Ser Ile Gly Gln Pro Phe Val Tyr Pro Arg Asn Asp Leu

180	185	190	
Ser Tyr Ala Gly Asn Phe Leu Asn Met Met Phe Ser Ala Pro Cys Glu			
195	200	205	
Pro Tyr Glu Val Asn Pro Ile Leu Glu Arg Ala Met Asp Arg Ile Leu			
210	215	220	
Ile Leu His Ala Asp His Glu Gln Asn Ala Ser Thr Ser Thr Val Arg			
225	230	235	240
Thr Ala Gly Ser Ser Gly Ala Asn Pro Phe Ala Cys Ile Ala Ala Gly			
245	250	255	
Ile Ala Ser Leu Trp Gly Pro Ala His Gly Gly Ala Asn Glu Ala Ala			
260	265	270	
Leu Lys Met Leu Glu Glu Ile Ser Ser Val Lys His Ile Pro Glu Phe			
275	280	285	
Val Arg Arg Ala Lys Asp Lys Asn Asp Ser Phe Arg Leu Met Gly Phe			
290	295	300	
Gly His Arg Val Tyr Lys Asn Tyr Asp Pro Arg Ala Thr Val Met Arg			
305	310	315	320
Glu Thr Cys His Glu Val Leu Lys Glu Leu Gly Thr Lys Asp Asp Leu			

325 330 335

Leu Glu Val Ala Met Glu Leu Glu Asn Ile Ala Leu Asn Asp Pro Tyr

340 345 350

Phe Ile Glu Lys Lys Leu Tyr Pro Asn Val Asp Phe Tyr Ser Gly Ile

355 360 365

Ile Leu Lys Ala Met Gly Ile Pro Ser Ser Met Phe Thr Val Ile Phe

370 375 380

Ala Met Ala Arg Thr Val Gly Trp Ile Ala His Trp Ser Glu Met His

385 390 395 400

Ser Asp Gly Met Lys Ile Ala Arg Pro Arg Gln Leu Tyr Thr Gly Tyr

405 410 415

Glu Lys Arg Asp Phe Lys Ser Asp Ile Lys Arg

420 425

<210> 4

<211> 427

<212> PRT

<213> Escherichia coli

<220>

<221> PEPTIDE

<222> (1)..(427)

<223> GltA

<400> 4

Met Ala Asp Thr Lys Ala Lys Leu Thr Leu Asn Gly Asp Thr Ala Val

1 5 10 15

Glu Leu Asp Val Leu Lys Gly Thr Leu Gly Gln Asp Val Ile Asp Ile

20 25 30

Arg Thr Leu Gly Ser Lys Gly Val Phe Thr Phe Asp Pro Gly Phe Thr

35 40 45

Ser Thr Ala Ser Cys Glu Ser Lys Ile Thr Phe Ile Asp Gly Asp Glu

50 55 60

Gly Ile Leu Leu His Arg Gly Phe Pro Ile Asp Gln Leu Ala Thr Asp

65 70 75 80

Ser Asn Tyr Leu Glu Val Cys Tyr Ile Leu Leu Asn Gly Glu Lys Pro

85 90 95

Thr Gln Glu Gln Tyr Asp Glu Phe Lys Thr Thr Val Thr Arg His Thr

100 105 110

Met Ile His Glu Gln Ile Thr Arg Leu Phe His Ala Phe Arg Arg Asp

115 120 125

Ser His Pro Met Ala Val Met Cys Gly Ile Thr Gly Ala Leu Ala Ala

130 135 140

Phe Tyr His Asp Ser Leu Asp Val Asn Asn Pro Arg His Arg Glu Ile

145 150 155 160

Ala Ala Phe Arg Leu Leu Ser Lys Met Pro Thr Met Ala Ala Met Cys

165 170 175

Tyr Lys Tyr Ser Ile Gly Gln Pro Phe Val Tyr Pro Arg Asn Asp Leu

180 185 190

Ser Tyr Ala Gly Asn Phe Leu Asn Met Met Phe Ser Thr Pro Cys Glu

195 200 205

Pro Tyr Glu Val Asn Pro Ile Leu Glu Arg Ala Met Asp Arg Ile Leu

210 215 220

Ile Leu His Ala Asp His Glu Gln Asn Ala Ser Thr Ser Thr Val Arg

225 230 235 240

Thr Ala Gly Ser Ser Gly Ala Asn Pro Phe Ala Cys Ile Ala Ala Gly

245 250 255

Ile Ala Ser Leu Trp Gly Pro Ala His Gly Gly Ala Asn Glu Ala Ala

260 265 270

Leu Lys Met Leu Glu Glu Ile Ser Ser Val Lys His Ile Pro Glu Phe

275 280 285

Val Arg Arg Ala Lys Asp Lys Asn Asp Ser Phe Arg Leu Met Gly Phe

290 295 300

Gly His Arg Val Tyr Lys Asn Tyr Asp Pro Arg Ala Thr Val Met Arg

305 310 315 320

Glu Thr Cys His Glu Val Leu Lys Glu Leu Gly Thr Lys Asp Asp Leu

325 330 335

Leu Glu Val Ala Met Glu Leu Glu Asn Ile Ala Leu Asn Asp Pro Tyr

340 345 350

Phe Ile Glu Lys Lys Leu Tyr Pro Asn Val Asp Phe Tyr Ser Gly Ile

355 360 365

Ile Leu Lys Ala Met Gly Ile Pro Ser Ser Met Phe Thr Val Ile Phe

370 375 380

Ala Met Ala Arg Thr Val Gly Trp Ile Ala His Trp Ser Glu Met His

385 390 395 400

Ser Asp Gly Met Lys Ile Ala Arg Pro Arg Gln Leu Tyr Thr Gly Tyr

405

410

415

Glu Lys Arg Asp Phe Lys Ser Asp Ile Lys Arg

420

425

<210> 5

<211> 1284

<212> DNA

<213> Artificial Sequence

<220>

<223> GltA A145

<400> 5

atggctgata caaaagcaaa actcacctc aacggggata cagctgttga actggatgtg 60

ctgaaaggca cgctgggtca agatgttatt gatatccgta ctctcggttc aaaaggtgtg 120

ttcacctttg acccaggctt cactcaacc gcatcctgcg aatctaaaat tacttttatt 180

gatggtgatg aaggtatatt gctgcaccgc ggtttccga tcgatcagct ggcgaccgat 240

tctaactacc tggaagtttg ttacatcctg ctgaatggtg aaaaaccgac tcaggaacag 300

tatgacgaat ttaaaactac ggtgaccgt cataccatga tccacgagca gattaccgt	360
ctgttccatg ctttccgtcg cgactcgcat ccaatggcag tcatgtgtgg tattaccggc	420
gcgctggcgg cgttcgcga cgactcgctg gatgttaaca atcctcgtca ccgtgaaatt	480
gccgcgttcc gcctgctgtc gaaaatgccg accatggccg cgatgtgtta caagtattcc	540
attggtcagc catttgttta cccgcgaac gatctctct acgccggttaa cttctgaat	600
atgatgttct ccacgccgtg cgaaccgtat gaagttaatc cgattctgga acgtgctatg	660
gaccgtattc tgatctgca cgctgacat gaacagaacg cctctacctc caccgtgcgt	720
accgctggct cttcgggtgc gaaccggtt gcctgtatcg cagcaggat tgcttcaatg	780
tggggacctg cgcacggcgg tgctaacgaa gcggcgctga aaatgctgga agaaatcagc	840
tccgttaaac acattccgga atttggtcgt cgtgcgaaag acaaaaatga ttctttccgc	900
ctgatgggct tcggtcaccg cgtgtacaaa aattacgacc cgcgccgac cgtaatgcgt	960
gaaacctgcc atgaagtgt gaaagagctg ggcacgaagg atgacctgt ggaagtggct	1020
atggagctgg aaaacatcg cgtgaacgac ccgtacttta tcgagaagaa actgtaccg	1080
aacgtcgatt tctactctgg tatcatcctg aaagcgatgg gtattccgtc ttcatgttc	1140

accgtcattt tcgcaatggc acgtaccgtt ggctggatcg cccactggag cgaaatgcac 1200

agtgacggta tgaagattgc ccgtccgct cagctgtata caggatatga aaaacgcgac 1260

tttaaaagcg atatcaagcg ttaa 1284

<210> 6

<211> 1284

<212> DNA

<213> Artificial Sequence

<220>

<223> GltA A167

<400> 6

atggctgata caaaagcaaa actcaccctc aacggggata cagctgttga actggatgtg 60

ctgaaaggca cgctgggtca agatgttatt gatatccgta ctctcggttc aaaaggtgtg 120

ttcaccttgg acccaggctt cacttcaacc gcatcctgcg aatctaaaat tacttttatt 180

gatggtgatg aaggtatatt gctgcaccgc ggtttccga tcgatcagct ggcgaccgat 240

tctaactacc tggaagtttg ttacatcctg ctgaatggtg aaaaaccgac tcaggaacag 300

tatgacgaat ttaaaactac ggtgaccgt cataccatga tccacgagca gattaccgt	360
ctgttccatg cttccgtcg cgactcgcat ccaatggcag tcatgtgtgg tattaccggc	420
gcgctggcgg cgttctatca cgactcgctg gatgttaaca atcctcgta ccgtgaaatt	480
gccgcgttcc gcctgctgtc ggcgatgccg accatggccg cgatgtgtta caagtattcc	540
attggtcagc catttgttta cccgcgaac gatctctct acgccggttaa cttctgaat	600
atgatgttct ccacgccgtg cgaaccgtat gaagttaatc cgattctgga acgtgctatg	660
gaccgtattc tgatctgca cgctgaccat gaacagaacg cctctacctc caccgtgcgt	720
accgtggct cttcgggtgc gaaccggtt gcctgtatcg cagcaggat tgcttcactg	780
tggggacctg cgcacggcgg tgctaacgaa gcggcgctga aaatgctgga agaaatcagc	840
tccgttaaac acattccgga attgttcgt cgtgcgaaag acaaaaatga ttctttccgc	900
ctgatgggct tcggtcaccg cgtgtacaaa aattacgacc cgcgcgccac cgtaatgcgt	960
gaaacctgcc atgaagtgt gaaagagctg ggcacgaagg atgacctgt ggaagtggct	1020
atggagctgg aaaacatcg cgtgaacgac ccgtacttta tcgagaagaa actgtaccg	1080

aacgtcgatt tctactctgg tatcatcctg aaagcgatgg gtattccgtc ttccatgttc 1140

accgtcattt tcgcaatggc acgtaccgtt ggctggatcg ccactggag cgaaatgcac 1200

agtgcaggta tgaagattgc ccgtccgct cagctgtata caggatatga aaaacgac 1260

tttaaaagcg atatcaagcg ttaa 1284

<210> 7

<211> 1284

<212> DNA

<213> Artificial Sequence

<220>

<223> GltA A204

<400> 7

atggctgata caaaagcaaa actcacctc aacggggata cagctgttga actggatgtg 60

ctgaaaggca cgctgggtca agatgttatt gatatccgta ctctcggtc aaaaggtgtg 120

ttcaccttg acccaggctt cactcaacc gcatcctgcg aatctaaaat tacttttatt 180

gatggtgatg aaggtatatt gctgcaccgc ggtttccga tcgatcagct ggcgaccgat 240

tctaactacc tggaagtttg ttacatcctg ctgaatggg aaaaaccgac tcaggaacag	300
tatgacgaat ttaaaactac ggtgacccgt cataccatga tccacgagca gattacccgt	360
ctgttccatg ctttccgtcg cgactcgcat ccaatggcag tcatgtgtgg tattaccggc	420
gcgctggcgg cgttctatca cgactcgctg gatgttaaca atcctcgta cctgaaatt	480
gccgcgttcc gcctgctgc gaaaatgccg accatggccg cgatgtgtta caagtattcc	540
attggtcagc catttgttta cccgcgcaac gatctctct acgccggtta cttctgaat	600
atgatgttct ccgcgccgtg cgaaccgtat gaagttaatc cgattctgga acgtgctatg	660
gaccgtattc tgatctgca cgctgacat gaacagaacg cctctacctc caccgtgcgt	720
accgctggct cttcgggtgc gaaccgttt gcctgtatcg cagcaggat tgcttcactg	780
tggggacctg cgcacggcgg tgctaacgaa gcggcgctga aaatgctgga agaaatcagc	840
tccgttaaac acattccgga attgttcgt cgtgcgaaag acaaaaatga ttctttccgc	900
ctgatgggct tcggtcaccg cgtgtacaaa aattacgacc cgcgcgccac cgtaatgcgt	960
gaaacctgcc atgaagtgt gaaagagctg ggcacgaagg atgacctgt ggaagtggct	1020
atggagctgg aaaacatcgc gctgaacgac ccgtacttta tcgagaagaa actgtaccg	1080

aacgtcgatt tctactctgg tatcatcctg aaagcgatgg gtattccgtc ttccatgttc 1140

accgtcattt tcgcaatggc acgtaccgtt ggctggatcg cccactggag cgaaatgcac 1200

agtgacggta tgaagattgc cgtccgct cagctgtata caggatatga aaaacgac 1260

tttaaaagcg atatcaagcg ttaa 1284

<210> 8

<211> 1284

<212> DNA

<213> Escherichia coli

<220>

<221> gene

<222> (1)..(1284)

<223> GltA

<400> 8

atggctgata caaaagcaaa actcaccctc aacggggata cagctgttga actggatgtg 60

ctgaaaggca cgctgggtca agatgttatt gatatccgta ctctcggttc aaaaggtgtg 120

ttcacctttg acccaggctt cactcaacc gcatcctgcg aatctaaaat tacttttatt 180

gatggtgatg aaggtathtt gctgcaccgc ggtttcccga tcgatcagct ggcgaccgat	240
tctaactacc tggaagtttg ttacatcctg ctgaatgggtg aaaaaccgac tcaggaacag	300
tatgacgaat ttaaaactac ggtgaccgt cataccatga tccacgagca gattaccgt	360
ctgttccatg ctttccgtcg cgactcgcat ccaatggcag tcatgtgtgg tattaccggc	420
gcgctggcgg cgttctatca cgactcgctg gatgttaaca atcctcgta ccgtgaaatt	480
gccgcttcc gcctgctgtc gaaaatgccg accatggccg cgatgtgtta caagtattcc	540
attggtcagc catttgttta cccgcgaac gatctctct acgccggtta cttcctgaat	600
atgatgttct ccacgccgtg cgaaccgtat gaagttaatc cgattctgga acgtgctatg	660
gaccgtattc tgatctgca cgctgaccat gaacagaacg cctctacctc caccgtgcgt	720
accgtggct cttcgggtgc gaaccgttt gcctgtatcg cagcaggtat tgcttcactg	780
tggggacctg cgcacggcgg tgctaacgaa gcggcgctga aaatgctgga agaaatcagc	840
tccgttaaac acattccgga atttgttcgt cgtgcgaaag acaaaaatga ttctttccgc	900
ctgatgggct tcggtcaccg cgtgtacaaa aattacgacc cgcgcgccac cgtaatgcgt	960

gaaacctgcc atgaagtgct gaaagagctg ggcacgaagg atgacctgct ggaagtggct 1020

atggagctgg aaaacatcgc gctgaacgac ccgtacttta tcgagaagaa actgtaccg 1080

aacgtcgatt tctactctgg tatcatcctg aaagcgatgg gtattccgtc ttccatgttc 1140

accgtcattt tcgcaatggc acgtaccgtt ggctggatcg cccactggag cgaaatgcac 1200

agtgacggta tgaagattgc ccgtccgct cagctgtata caggatatga aaaacgacgac 1260

tttaaaagcg atatcaagcg ttaa 1284

<210> 9

<211> 386

<212> PRT

<213> Escherichia coli

<220>

<221> PEPTIDE

<222> (1)..(386)

<223> metB

<400> 9

Met Thr Arg Lys Gln Ala Thr Ile Ala Val Arg Ser Gly Leu Asn Asp

1 5 10 15

Asp Glu Gln Tyr Gly Cys Val Val Pro Pro Ile His Leu Ser Ser Thr

20 25 30

Tyr Asn Phe Thr Gly Phe Asn Glu Pro Arg Ala His Asp Tyr Ser Arg

35 40 45

Arg Gly Asn Pro Thr Arg Asp Val Val Gln Arg Ala Leu Ala Glu Leu

50 55 60

Glu Gly Gly Ala Gly Ala Val Leu Thr Asn Thr Gly Met Ser Ala Ile

65 70 75 80

His Leu Val Thr Thr Val Phe Leu Lys Pro Gly Asp Leu Leu Val Ala

85 90 95

Pro His Asp Cys Tyr Gly Gly Ser Tyr Arg Leu Phe Asp Ser Leu Ala

100 105 110

Lys Arg Gly Cys Tyr Arg Val Leu Phe Val Asp Gln Gly Asp Glu Gln

115 120 125

Ala Leu Arg Ala Ala Leu Ala Glu Lys Pro Lys Leu Val Leu Val Glu

130 135 140

Ser Pro Ser Asn Pro Leu Leu Arg Val Val Asp Ile Ala Lys Ile Cys

145 150 155 160

His Leu Ala Arg Glu Val Gly Ala Val Ser Val Val Asp Asn Thr Phe

165 170 175

Leu Ser Pro Ala Leu Gln Asn Pro Leu Ala Leu Gly Ala Asp Leu Val

180 185 190

Leu His Ser Cys Thr Lys Tyr Leu Asn Gly His Ser Asp Val Val Ala

195 200 205

Gly Val Val Ile Ala Lys Asp Pro Asp Val Val Thr Glu Leu Ala Trp

210 215 220

Trp Ala Asn Asn Ile Gly Val Thr Gly Gly Ala Phe Asp Ser Tyr Leu

225 230 235 240

Leu Leu Arg Gly Leu Arg Thr Leu Val Pro Arg Met Glu Leu Ala Gln

245 250 255

Arg Asn Ala Gln Ala Ile Val Lys Tyr Leu Gln Thr Gln Pro Leu Val

260 265 270

Lys Lys Leu Tyr His Pro Ser Leu Pro Glu Asn Gln Gly His Glu Ile

275 280 285

Ala Ala Arg Gln Gln Lys Gly Phe Gly Ala Met Leu Ser Phe Glu Leu

290 295 300

Asp Gly Asp Glu Gln Thr Leu Arg Arg Phe Leu Gly Gly Leu Ser Leu

305 310 315 320

Phe Thr Leu Ala Glu Ser Leu Gly Gly Val Glu Ser Leu Ile Ser His

325 330 335

Ala Ala Thr Met Thr His Ala Gly Met Ala Pro Glu Ala Arg Ala Ala

340 345 350

Ala Gly Ile Ser Glu Thr Leu Leu Arg Ile Ser Thr Gly Ile Glu Asp

355 360 365

Gly Glu Asp Leu Ile Ala Asp Leu Glu Asn Gly Phe Arg Ala Ala Asn

370 375 380

Lys Gly

385

<210> 10

<211> 1161

<212> DNA

<213> Escherichia coli

<220>

<221> gene

<222> (1)..(1161)

<223> metB

<400> 10

atgacgcgta aacaggccac catcgagtg cgtacgggt taaatgacga cgaacagtat 60

ggttgcgttg tcccaccgat ccatctttcc agcacctata actttaccgg attaatgaa 120

ccgcgcgcgc atgattactc gcgtcgggc aaccaacgc gcgatgtggt tcagcgtgcg 180

ctggcagaac tggaagggtg tgctgggtgca gtacttacta ataccggcat gtccgcgatt 240

cacctggtaa cgaccgtctt ttgaaacct ggcatctgc tggttgcgc gcacgactgc 300

tacggcggta gctatgcct gttcgacagt ctggcgaaac gcggttgcta tcgctgttg 360

ttgttgatc aaggcgatga acaggcatta cgggcagcgc tggcagaaaa acccaaactg 420

gtactgtag aaagccaag taatccattg ttacgcgtcg tggatattgc gaaaatctgc 480

catctggcaa gggaagtcgg ggcggtgagc gtggtggata acaccttctt aagcccgcga 540

ttacaaaatc cgctggcatt aggtgccgat ctggtgttg attcatgcac gaaatatctg 600

aacggtcact cagacgtagt ggccggcgtg gtgattgcta aagaccgga cgttgctact 660

gaactggcct ggtgggcaaa caatattggc gtgacgggcg gcgcgttga cagctatctg	720
ctgctacgtg ggttgccaac gctggtgccg cgtatggagc tggcgagcg caacgcgag	780
gcgattgtga aatactgca aaccagccg ttggtgaaaa aactgtatca cccgtcgtt	840
ccggaaaatc aggggcatga aattgccgcg gccagcaaa aaggcttgg cgcaatgtg	900
agtttgaac tggatggcga tgagcagacg ctgcgtcgtt tcctgggcgg gctgtcgtt	960
tttacgctgg cggaatcatt agggggagtg gaaagtttaa tctctcacgc cgcaaccatg	1020
acacatgcag gcatggcacc agaagcgcgt gctgccgccg ggatctccga gacgtgctg	1080
cgatatcca ccggtattga agatggcgaa gatttaattg ccgacctgga aaatggcttc	1140
cgggctgcaa acaaggggta a	1161

<210> 11

<211> 310

<212> PRT

<213> Escherichia coli

<220>

<221> PEPTIDE

<222> (1)..(310)

<223> thrB

<400> 11

Met Val Lys Val Tyr Ala Pro Ala Ser Ser Ala Asn Met Ser Val Gly

1 5 10 15

Phe Asp Val Leu Gly Ala Ala Val Thr Pro Val Asp Gly Ala Leu Leu

20 25 30

Gly Asp Val Val Thr Val Glu Ala Ala Glu Thr Phe Ser Leu Asn Asn

35 40 45

Leu Gly Arg Phe Ala Asp Lys Leu Pro Ser Glu Pro Arg Glu Asn Ile

50 55 60

Val Tyr Gln Cys Trp Glu Arg Phe Cys Gln Glu Leu Gly Lys Gln Ile

65 70 75 80

Pro Val Ala Met Thr Leu Glu Lys Asn Met Pro Ile Gly Ser Gly Leu

85 90 95

Gly Ser Ser Ala Cys Ser Val Val Ala Ala Leu Met Ala Met Asn Glu

100 105 110

His Cys Gly Lys Pro Leu Asn Asp Thr Arg Leu Leu Ala Leu Met Gly

115 120 125

Glu Leu Glu Gly Arg Ile Ser Gly Ser Ile His Tyr Asp Asn Val Ala

130 135 140

Pro Cys Phe Leu Gly Gly Met Gln Leu Met Ile Glu Glu Asn Asp Ile

145 150 155 160

Ile Ser Gln Gln Val Pro Gly Phe Asp Glu Trp Leu Trp Val Leu Ala

165 170 175

Tyr Pro Gly Ile Lys Val Ser Thr Ala Glu Ala Arg Ala Ile Leu Pro

180 185 190

Ala Gln Tyr Arg Arg Gln Asp Cys Ile Ala His Gly Arg His Leu Ala

195 200 205

Gly Phe Ile His Ala Cys Tyr Ser Arg Gln Pro Glu Leu Ala Ala Lys

210 215 220

Leu Met Lys Asp Val Ile Ala Glu Pro Tyr Arg Glu Arg Leu Leu Pro

225 230 235 240

Gly Phe Arg Gln Ala Arg Gln Ala Val Ala Glu Ile Gly Ala Val Ala

245 250 255

Ser Gly Ile Ser Gly Ser Gly Pro Thr Leu Phe Ala Leu Cys Asp Lys

260 265 270

Pro Glu Thr Ala Gln Arg Val Ala Asp Trp Leu Gly Lys Asn Tyr Leu

275 280 285

Gln Asn Gln Glu Gly Phe Val His Ile Cys Arg Leu Asp Thr Ala Gly

290 295 300

Ala Arg Val Leu Glu Asn

305 310

<210> 12

<211> 933

<212> DNA

<213> Escherichia coli

<220>

<221> gene

<222> (1)..(933)

<223> thrB

<400> 12

atgggttaaag tttatgcccc ggcttcagtg gccaatatga gcgtcgggtt tgatgtgctc 60

ggggcggcgg tgacacctgt tgatggtgca ttgctcggag atgtagtcac gggtgaggcg 120

gcagagacat tcagtctcaa caacctcgga cgctttgccg ataagctgcc gtcagaacca	180
cgggaaaata tcgtttatca gtgctgggag cgttttgcc aggaactggg taagcaaatt	240
ccagtggcga tgacctgga aaagaatatg ccgatcggtt cgggcttagg ctccagtgcc	300
tgttcgggtg tcgcggcgct gatggcgatg aatgaacct gcggcaagcc gcttaatgac	360
actcgtttgc tggctttgat gggcgagctg gaaggccgta tctccggcag cattcattac	420
gacaacgtgg caccgtgttt tctcgggtgt atgcagttga tgatcgaaga aaacgacatc	480
atcagccagc aagtgccagg gtttgatgag tggctgtggg tgctggcgta tccggggatt	540
aaagtctcga cggcagaagc cagggctatt ttaccggcgc agtatcgccg ccaggattgc	600
attgcgcacg ggcgacatct ggcaggcttc attcacgcct gctattcccg tcagcctgag	660
cttgccgcga agctgatgaa agatgttatc gctgaaccct accgtgaacg gttactgcca	720
ggcttcggc aggcgcggca ggcggtcgcg gaaatcggcg cggtagcgag cggtatctcc	780
ggctccggcc cgacctgtt cgctctgtgt gacaagccgg aaaccgcca gcgcgttgcc	840
gactgggttg gtaagaacta cctgcaaaat caggaagggt ttgttcatat ttgccggctg	900
gatacggcgg gcgcacgagt actggaaaac taa	933

<210> 13

<211> 379

<212> PRT

<213> *Leptospira meyeri*

<220>

<221> PEPTIDE

<222> (1)..(379)

<223> homoserine O-acetyltransferase

<400> 13

Met Pro Thr Ser Glu Gln Asn Glu Phe Ser His Gly Ser Val Gly Val

1 5 10 15

Val Tyr Thr Gln Ser Ile Arg Phe Glu Ser Leu Thr Leu Glu Gly Gly

20 25 30

Glu Thr Ile Thr Pro Leu Glu Ile Ala Tyr Glu Thr Tyr Gly Thr Leu

35 40 45

Asn Glu Lys Lys Asp Asn Ala Ile Leu Val Cys His Ala Leu Ser Gly

50 55 60

Asp Ala His Ala Ala Gly Phe His Glu Gly Asp Lys Arg Pro Gly Trp

65 70 75 80

Trp Asp Tyr Tyr Ile Gly Pro Gly Lys Ser Phe Asp Thr Asn Arg Tyr

85 90 95

Phe Ile Ile Ser Ser Asn Val Ile Gly Gly Cys Lys Gly Ser Ser Gly

100 105 110

Pro Leu Thr Ile Asn Gly Lys Asn Gly Lys Pro Phe Gln Ser Thr Phe

115 120 125

Pro Phe Val Ser Ile Gly Asp Met Val Asn Ala Gln Glu Lys Leu Ile

130 135 140

Ser His Phe Gly Ile His Lys Leu Phe Ala Val Ala Gly Gly Ser Met

145 150 155 160

Gly Gly Met Gln Ala Leu Gln Trp Ser Val Ala Tyr Pro Asp Arg Leu

165 170 175

Lys Asn Cys Ile Val Met Ala Ser Ser Ser Glu His Ser Ala Gln Gln

180 185 190

Ile Ala Phe Asn Glu Val Gly Arg Gln Ala Ile Leu Ser Asp Pro Asn

195 200 205

Trp Asn Gln Gly Leu Tyr Thr Gln Glu Asn Arg Pro Ser Lys Gly Leu

210	215	220	
Ala Leu Ala Arg Met Met Gly His Ile Thr Tyr Leu Ser Asp Glu Met			
225	230	235	240
Met Arg Glu Lys Phe Gly Arg Lys Pro Pro Lys Gly Asn Ile Gln Ser			
245	250	255	
Thr Asp Phe Ala Val Gly Ser Tyr Leu Ile Tyr Gln Gly Glu Ser Phe			
260	265	270	
Val Asp Arg Phe Asp Ala Asn Ser Tyr Ile Tyr Val Thr Lys Ala Leu			
275	280	285	
Asp His Phe Ser Leu Gly Thr Gly Lys Glu Leu Thr Lys Val Leu Ala			
290	295	300	
Lys Val Arg Cys Arg Phe Leu Val Val Ala Tyr Thr Ser Asp Trp Leu			
305	310	315	320
Tyr Pro Pro Tyr Gln Ser Glu Glu Ile Val Lys Ser Leu Glu Val Asn			
325	330	335	
Ala Val Pro Val Ser Phe Val Glu Leu Asn Asn Pro Ala Gly Arg His			
340	345	350	
Asp Ser Phe Leu Leu Pro Ser Glu Gln Gln Asp Ser Ile Leu Arg Asp			

355 360 365

Phe Leu Ser Ser Thr Asp Glu Gly Val Phe Leu

370 375

<210> 14

<211> 379

<212> PRT

<213> Corynebacterium glutamicum

<220>

<221> PEPTIDE

<222> (1)..(379)

<223> homoserine O-acetyltransferase

<400> 14

Met Pro Thr Leu Ala Pro Ser Gly Gln Leu Glu Ile Gln Ala Ile Gly

1 5 10 15

Asp Val Ser Thr Glu Ala Gly Ala Ile Ile Thr Asn Ala Glu Ile Ala

20 25 30

Tyr His Arg Trp Gly Glu Tyr Arg Val Asp Lys Glu Gly Arg Ser Asn

35 40 45

Val Val Leu Ile Glu His Ala Leu Thr Gly Asp Ser Asn Ala Ala Asp

50 55 60

Trp Trp Ala Asp Leu Leu Gly Pro Gly Lys Ala Ile Asn Thr Asp Ile

65 70 75 80

Tyr Cys Val Ile Cys Thr Asn Val Ile Gly Gly Cys Asn Gly Ser Thr

85 90 95

Gly Pro Gly Ser Met His Pro Asp Gly Asn Phe Trp Gly Asn Arg Phe

100 105 110

Pro Ala Thr Ser Ile Arg Asp Gln Val Asn Ala Glu Lys Gln Phe Leu

115 120 125

Asp Ala Leu Gly Ile Thr Thr Val Ala Ala Val Val Leu Leu Gly Gly

130 135 140

Ser Met Gly Gly Ala Arg Thr Leu Glu Trp Ala Ala Met Tyr Pro Glu

145 150 155 160

Thr Val Gly Ala Ala Ala Val Leu Ala Val Ser Ala Arg Ala Ser Ala

165 170 175

Trp Gln Ile Gly Ile Gln Ser Ala Gln Ile Lys Ala Ile Glu Asn Asp

180 185 190

His His Trp His Glu Gly Asn Tyr Tyr Glu Ser Gly Cys Asn Pro Ala

195 200 205

Thr Gly Leu Gly Ala Ala Arg Arg Ile Ala His Leu Thr Tyr Arg Gly

210 215 220

Glu Leu Glu Ile Asp Glu Arg Phe Gly Thr Lys Ala Gln Lys Asn Glu

225 230 235 240

Asn Pro Leu Gly Pro Tyr Arg Lys Pro Asp Gln Arg Phe Ala Val Glu

245 250 255

Ser Tyr Leu Asp Tyr Gln Ala Asp Lys Leu Val Gln Arg Phe Asp Ala

260 265 270

Gly Ser Tyr Val Leu Leu Thr Asp Ala Leu Asn Arg His Asp Ile Gly

275 280 285

Arg Asp Arg Gly Gly Leu Asn Lys Ala Leu Glu Ser Ile Lys Val Pro

290 295 300

Val Leu Val Ala Gly Val Asp Thr Asp Ile Leu Tyr Pro Tyr His Gln

305 310 315 320

Gln Glu His Leu Ser Arg Asn Leu Gly Asn Leu Leu Ala Met Ala Lys

325 330 335

Ile Val Ser Pro Val Gly His Asp Ala Phe Leu Thr Glu Ser Arg Gln

340 345 350

Met Asp Arg Ile Val Arg Asn Phe Phe Ser Leu Ile Ser Pro Asp Glu

355 360 365

Asp Asn Pro Ser Thr Tyr Ile Glu Phe Tyr Ile

370 375

<210> 15

<211> 334

<212> PRT

<213> Deinococcus radiodurans

<220>

<221> PEPTIDE

<222> (1)..(334)

<223> homoserine O-acetyltransferase

<400> 15

Met Thr Ala Val Leu Ala Gly His Ala Ser Ala Leu Leu Leu Thr Glu

1 5 10 15

Glu Pro Asp Cys Ser Gly Pro Gln Thr Val Val Leu Phe Arg Arg Glu

20 25 30

Pro Leu Leu Leu Asp Cys Gly Arg Ala Leu Ser Asp Val Arg Val Ala

35 40 45

Phe His Thr Tyr Gly Thr Pro Arg Ala Asp Ala Thr Leu Val Leu His

50 55 60

Ala Leu Thr Gly Asp Ser Ala Val His Glu Trp Trp Pro Asp Phe Leu

65 70 75 80

Gly Ala Gly Arg Pro Leu Asp Pro Ala Asp Asp Tyr Val Val Cys Ala

85 90 95

Asn Val Leu Gly Gly Cys Ala Gly Thr Thr Ser Ala Ala Glu Leu Ala

100 105 110

Ala Thr Cys Ser Gly Pro Val Pro Leu Ser Leu Arg Asp Met Ala Arg

115 120 125

Val Gly Arg Ala Leu Leu Asp Ser Leu Gly Val Arg Arg Val Arg Val

130 135 140

Ile Gly Ala Ser Met Gly Gly Met Leu Ala Tyr Ala Trp Leu Leu Glu

145 150 155 160

Cys Pro Asp Leu Val Glu Lys Ala Val Ile Ile Gly Ala Pro Ala Arg

165 170 175

His Ser Pro Trp Ala Ile Gly Leu Asn Thr Ala Ala Arg Ser Ala Ile

180 185 190

Ala Leu Ala Pro Gly Gly Glu Gly Leu Lys Val Ala Arg Gln Ile Ala

195 200 205

Met Leu Ser Tyr Arg Ser Pro Glu Ser Leu Ser Arg Thr Gln Ala Gly

210 215 220

Gln Arg Val Pro Gly Val Pro Ala Val Thr Ser Tyr Leu His Tyr Gln

225 230 235 240

Gly Glu Lys Leu Ala Ala Arg Phe Asp Glu Gln Thr Tyr Cys Ala Leu

245 250 255

Thr Trp Ala Met Asp Ala Phe Gln Pro Ser Ser Ala Asp Leu Lys Ala

260 265 270

Val Arg Ala Pro Val Leu Val Val Gly Ile Ser Ser Asp Leu Leu Tyr

275 280 285

Pro Ala Ala Glu Val Arg Ala Cys Ala Ala Glu Leu Pro His Ala Asp

290 295 300

Tyr Trp Glu Leu Gly Ser Ile His Gly His Asp Ala Phe Leu Met Asp

305 310 315 320

Pro Gln Asp Leu Pro Glu Arg Val Gly Ala Phe Leu Arg Ser

325

330

<210> 16

<211> 309

<212> PRT

<213> Escherichia coli

<220>

<221> PEPTIDE

<222> (1)..(309)

<223> homoserine O-succinyl transferase

<400> 16

Met Pro Ile Arg Val Pro Asp Glu Leu Pro Ala Val Asn Phe Leu Arg

1

5

10

15

Glu Glu Asn Val Phe Val Met Thr Thr Ser Arg Ala Ser Gly Gln Glu

20

25

30

Ile Arg Pro Leu Lys Val Leu Ile Leu Asn Leu Met Pro Lys Lys Ile

35

40

45

Glu Thr Glu Asn Gln Phe Leu Arg Leu Leu Ser Asn Ser Pro Leu Gln

50 55 60

Val Asp Ile Gln Leu Leu Arg Ile Asp Ser Arg Glu Ser Arg Asn Thr

65 70 75 80

Pro Ala Glu His Leu Asn Asn Phe Tyr Cys Asn Phe Glu Asp Ile Gln

85 90 95

Asp Gln Asn Phe Asp Gly Leu Ile Val Thr Gly Ala Pro Leu Gly Leu

100 105 110

Val Glu Phe Asn Asp Val Ala Tyr Trp Pro Gln Ile Lys Gln Val Leu

115 120 125

Glu Trp Ser Lys Asp His Val Thr Ser Thr Leu Phe Val Cys Trp Ala

130 135 140

Val Gln Ala Ala Leu Asn Ile Leu Tyr Gly Ile Pro Lys Gln Thr Arg

145 150 155 160

Thr Glu Lys Leu Ser Gly Val Tyr Glu His His Ile Leu His Pro His

165 170 175

Ala Leu Leu Thr Arg Gly Phe Asp Asp Ser Phe Leu Ala Pro His Ser

180 185 190

Arg Tyr Ala Asp Phe Pro Ala Ala Leu Ile Arg Asp Tyr Thr Asp Leu

195 200 205

Glu Ile Leu Ala Glu Thr Glu Glu Gly Asp Ala Tyr Leu Phe Ala Ser

210 215 220

Lys Asp Lys Arg Ile Ala Phe Val Thr Gly His Pro Glu Tyr Asp Ala

225 230 235 240

Gln Thr Leu Ala Gln Glu Phe Phe Arg Asp Val Glu Ala Gly Leu Asp

245 250 255

Pro Asp Val Pro Tyr Asn Tyr Phe Pro His Asn Asp Pro Gln Asn Thr

260 265 270

Pro Arg Ala Ser Trp Arg Ser His Gly Asn Leu Leu Phe Thr Asn Trp

275 280 285

Leu Asn Tyr Tyr Val Tyr Gln Ile Thr Pro Tyr Asp Leu Arg His Met

290 295 300

Asn Pro Thr Leu Asp

305

<210> 17

<211> 309

<212> PRT

<213> Artificial Sequence

<220>

<223> Variant polypeptide having homoserine O-acetyl transferase
activity, metA EL

<400> 17

Met Pro Ile Arg Val Pro Asp Glu Leu Pro Ala Val Asn Phe Leu Arg

1 5 10 15

Glu Glu Asn Val Phe Val Met Thr Thr Ser Arg Ala Ser Gly Gln Glu

20 25 30

Ile Arg Pro Leu Lys Val Leu Ile Leu Asn Leu Met Pro Lys Lys Ile

35 40 45

Glu Thr Glu Asn Gln Phe Leu Arg Leu Leu Ser Asn Ser Pro Leu Gln

50 55 60

Val Asp Ile Gln Leu Leu Arg Ile Asp Ser Arg Glu Ser Arg Asn Thr

65 70 75 80

Pro Ala Glu His Leu Asn Asn Phe Tyr Cys Asn Phe Glu Asp Ile Gln

85 90 95

Asp Gln Asn Phe Asp Gly Leu Ile Val Thr Gly Ala Pro Leu Glu Leu

100	105	110	
Val Glu Phe Asn Asp Val Ala Tyr Trp Pro Gln Ile Lys Gln Val Leu			
115	120	125	
Glu Trp Ser Lys Asp His Val Thr Ser Thr Leu Phe Val Cys Trp Ala			
130	135	140	
Val Gln Ala Ala Leu Asn Ile Leu Tyr Gly Ile Pro Lys Gln Thr Arg			
145	150	155	160
Thr Glu Lys Leu Ser Gly Val Tyr Glu His His Ile Leu His Pro His			
165	170	175	
Ala Leu Leu Thr Arg Gly Phe Asp Asp Ser Phe Leu Ala Pro His Ser			
180	185	190	
Arg Tyr Ala Asp Phe Pro Ala Ala Leu Ile Arg Asp Tyr Thr Asp Leu			
195	200	205	
Glu Ile Leu Ala Glu Thr Glu Glu Gly Asp Ala Tyr Leu Phe Ala Ser			
210	215	220	
Lys Asp Lys Arg Ile Ala Phe Val Thr Gly His Pro Glu Tyr Asp Ala			
225	230	235	240
Gln Thr Leu Ala Gln Glu Phe Phe Arg Asp Val Glu Ala Gly Leu Asp			

245	250	255
Pro Asp Val Pro Tyr Asn Tyr Phe Pro His Asn Asp Pro Gln Asn Thr		
260	265	270
Pro Arg Ala Ser Trp Arg Ser His Gly Asn Leu Leu Phe Thr Asn Trp		
275	280	285
Leu Asn Tyr Tyr Val Tyr Gln Ile Thr Pro Tyr Asp Leu Arg His Met		
290	295	300
Asn Pro Thr Leu Asp		
305		
<210> 18		
<211> 309		
<212> PRT		
<213> Artificial Sequence		
<220>		
<223> Variant polypeptide having homoserine O-acetyl transferase		
activity, metA ET		
<400> 18		
Met Pro Ile Arg Val Pro Asp Glu Leu Pro Ala Val Asn Phe Leu Arg		

1 5 10 15

Glu Glu Asn Val Phe Val Met Thr Thr Ser Arg Ala Ser Gly Gln Glu

20 25 30

Ile Arg Pro Leu Lys Val Leu Ile Leu Asn Leu Met Pro Lys Lys Ile

35 40 45

Glu Thr Glu Asn Gln Phe Leu Arg Leu Leu Ser Asn Ser Pro Leu Gln

50 55 60

Val Asp Ile Gln Leu Leu Arg Ile Asp Ser Arg Glu Ser Arg Asn Thr

65 70 75 80

Pro Ala Glu His Leu Asn Asn Phe Tyr Cys Asn Phe Glu Asp Ile Gln

85 90 95

Asp Gln Asn Phe Asp Gly Leu Ile Val Thr Gly Ala Pro Leu Glu Thr

100 105 110

Val Glu Phe Asn Asp Val Ala Tyr Trp Pro Gln Ile Lys Gln Val Leu

115 120 125

Glu Trp Ser Lys Asp His Val Thr Ser Thr Leu Phe Val Cys Trp Ala

130 135 140

Val Gln Ala Ala Leu Asn Ile Leu Tyr Gly Ile Pro Lys Gln Thr Arg

145 150 155 160

Thr Glu Lys Leu Ser Gly Val Tyr Glu His His Ile Leu His Pro His

165 170 175

Ala Leu Leu Thr Arg Gly Phe Asp Asp Ser Phe Leu Ala Pro His Ser

180 185 190

Arg Tyr Ala Asp Phe Pro Ala Ala Leu Ile Arg Asp Tyr Thr Asp Leu

195 200 205

Glu Ile Leu Ala Glu Thr Glu Glu Gly Asp Ala Tyr Leu Phe Ala Ser

210 215 220

Lys Asp Lys Arg Ile Ala Phe Val Thr Gly His Pro Glu Tyr Asp Ala

225 230 235 240

Gln Thr Leu Ala Gln Glu Phe Phe Arg Asp Val Glu Ala Gly Leu Asp

245 250 255

Pro Asp Val Pro Tyr Asn Tyr Phe Pro His Asn Asp Pro Gln Asn Thr

260 265 270

Pro Arg Ala Ser Trp Arg Ser His Gly Asn Leu Leu Phe Thr Asn Trp

275 280 285

Leu Asn Tyr Tyr Val Tyr Gln Ile Thr Pro Tyr Asp Leu Arg His Met

290 295 300

Asn Pro Thr Leu Asp

305

<210> 19

<211> 309

<212> PRT

<213> Artificial Sequence

<220>

<223> Variant polypeptide having homoserine O-acetyl transferase
activity, metA EH

<400> 19

Met Pro Ile Arg Val Pro Asp Glu Leu Pro Ala Val Asn Phe Leu Arg

1 5 10 15

Glu Glu Asn Val Phe Val Met Thr Thr Ser Arg Ala Ser Gly Gln Glu

20 25 30

Ile Arg Pro Leu Lys Val Leu Ile Leu Asn Leu Met Pro Lys Lys Ile

35 40 45

Glu Thr Glu Asn Gln Phe Leu Arg Leu Leu Ser Asn Ser Pro Leu Gln

50 55 60

Val Asp Ile Gln Leu Leu Arg Ile Asp Ser Arg Glu Ser Arg Asn Thr

65 70 75 80

Pro Ala Glu His Leu Asn Asn Phe Tyr Cys Asn Phe Glu Asp Ile Gln

85 90 95

Asp Gln Asn Phe Asp Gly Leu Ile Val Thr Gly Ala Pro Leu Glu His

100 105 110

Val Glu Phe Asn Asp Val Ala Tyr Trp Pro Gln Ile Lys Gln Val Leu

115 120 125

Glu Trp Ser Lys Asp His Val Thr Ser Thr Leu Phe Val Cys Trp Ala

130 135 140

Val Gln Ala Ala Leu Asn Ile Leu Tyr Gly Ile Pro Lys Gln Thr Arg

145 150 155 160

Thr Glu Lys Leu Ser Gly Val Tyr Glu His His Ile Leu His Pro His

165 170 175

Ala Leu Leu Thr Arg Gly Phe Asp Asp Ser Phe Leu Ala Pro His Ser

180 185 190

Arg Tyr Ala Asp Phe Pro Ala Ala Leu Ile Arg Asp Tyr Thr Asp Leu

195 200 205

Glu Ile Leu Ala Glu Thr Glu Glu Gly Asp Ala Tyr Leu Phe Ala Ser

210 215 220

Lys Asp Lys Arg Ile Ala Phe Val Thr Gly His Pro Glu Tyr Asp Ala

225 230 235 240

Gln Thr Leu Ala Gln Glu Phe Phe Arg Asp Val Glu Ala Gly Leu Asp

245 250 255

Pro Asp Val Pro Tyr Asn Tyr Phe Pro His Asn Asp Pro Gln Asn Thr

260 265 270

Pro Arg Ala Ser Trp Arg Ser His Gly Asn Leu Leu Phe Thr Asn Trp

275 280 285

Leu Asn Tyr Tyr Val Tyr Gln Ile Thr Pro Tyr Asp Leu Arg His Met

290 295 300

Asn Pro Thr Leu Asp

305

<210> 20

<211> 883

<212> PRT

<213> Escherichia coli

<220>

<221> PEPTIDE

<222> (1)..(883)

<223> phosphoenolpyruvate carboxylase

<400> 20

Met Asn Glu Gln Tyr Ser Ala Leu Arg Ser Asn Val Ser Met Leu Gly

1 5 10 15

Lys Val Leu Gly Glu Thr Ile Lys Asp Ala Leu Gly Glu His Ile Leu

20 25 30

Glu Arg Val Glu Thr Ile Arg Lys Leu Ser Lys Ser Ser Arg Ala Gly

35 40 45

Asn Asp Ala Asn Arg Gln Glu Leu Leu Thr Thr Leu Gln Asn Leu Ser

50 55 60

Asn Asp Glu Leu Leu Pro Val Ala Arg Ala Phe Ser Gln Phe Leu Asn

65 70 75 80

Leu Ala Asn Thr Ala Glu Gln Tyr His Ser Ile Ser Pro Lys Gly Glu

85 90 95

Ala Ala Ser Asn Pro Glu Val Ile Ala Arg Thr Leu Arg Lys Leu Lys

100 105 110

Asn Gln Pro Glu Leu Ser Glu Asp Thr Ile Lys Lys Ala Val Glu Ser

115 120 125

Leu Ser Leu Glu Leu Val Leu Thr Ala His Pro Thr Glu Ile Thr Arg

130 135 140

Arg Thr Leu Ile His Lys Met Val Glu Val Asn Ala Cys Leu Lys Gln

145 150 155 160

Leu Asp Asn Lys Asp Ile Ala Asp Tyr Glu His Asn Gln Leu Met Arg

165 170 175

Arg Leu Arg Gln Leu Ile Ala Gln Ser Trp His Thr Asp Glu Ile Arg

180 185 190

Lys Leu Arg Pro Ser Pro Val Asp Glu Ala Lys Trp Gly Phe Ala Val

195 200 205

Val Glu Asn Ser Leu Trp Gln Gly Val Pro Asn Tyr Leu Arg Glu Leu

210 215 220

Asn Glu Gln Leu Glu Glu Asn Leu Gly Tyr Lys Leu Pro Val Glu Phe

225 230 235 240

Val Pro Val Arg Phe Thr Ser Trp Met Gly Gly Asp Arg Asp Gly Asn

245 250 255

Pro Asn Val Thr Ala Asp Ile Thr Arg His Val Leu Leu Leu Ser Arg

260 265 270

Trp Lys Ala Thr Asp Leu Phe Leu Lys Asp Ile Gln Val Leu Val Ser

275 280 285

Glu Leu Ser Met Val Glu Ala Thr Pro Glu Leu Leu Ala Leu Val Gly

290 295 300

Glu Glu Gly Ala Ala Glu Pro Tyr Arg Tyr Leu Met Lys Asn Leu Arg

305 310 315 320

Ser Arg Leu Met Ala Thr Gln Ala Trp Leu Glu Ala Arg Leu Lys Gly

325 330 335

Glu Glu Leu Pro Lys Pro Glu Gly Leu Leu Thr Gln Asn Glu Glu Leu

340 345 350

Trp Glu Pro Leu Tyr Ala Cys Tyr Gln Ser Leu Gln Ala Cys Gly Met

355 360 365

Gly Ile Ile Ala Asn Gly Asp Leu Leu Asp Thr Leu Arg Arg Val Lys

370 375 380

Cys Phe Gly Val Pro Leu Val Arg Ile Asp Ile Arg Gln Glu Ser Thr

385 390 395 400

Arg His Thr Glu Ala Leu Gly Glu Leu Thr Arg Tyr Leu Gly Ile Gly

405 410 415

Asp Tyr Glu Ser Trp Ser Glu Ala Asp Lys Gln Ala Phe Leu Ile Arg

420 425 430

Glu Leu Asn Ser Lys Arg Pro Leu Leu Pro Arg Asn Trp Gln Pro Ser

435 440 445

Ala Glu Thr Arg Glu Val Leu Asp Thr Cys Gln Val Ile Ala Glu Ala

450 455 460

Pro Gln Gly Ser Ile Ala Ala Tyr Val Ile Ser Met Ala Lys Thr Pro

465 470 475 480

Ser Asp Val Leu Ala Val His Leu Leu Leu Lys Glu Ala Gly Ile Gly

485 490 495

Phe Ala Met Pro Val Ala Pro Leu Phe Glu Thr Leu Asp Asp Leu Asn

500 505 510

Asn Ala Asn Asp Val Met Thr Gln Leu Leu Asn Ile Asp Trp Tyr Arg

515 520 525

Gly Leu Ile Gln Gly Lys Gln Met Val Met Ile Gly Tyr Ser Asp Ser

530 535 540

Ala Lys Asp Ala Gly Val Met Ala Ala Ser Trp Ala Gln Tyr Gln Ala

545 550 555 560

Gln Asp Ala Leu Ile Lys Thr Cys Glu Lys Ala Gly Ile Glu Leu Thr

565 570 575

Leu Phe His Gly Arg Gly Gly Ser Ile Gly Arg Gly Gly Ala Pro Ala

580 585 590

His Ala Ala Leu Leu Ser Gln Pro Pro Gly Ser Leu Lys Gly Gly Leu

595 600 605

Arg Val Thr Glu Gln Gly Glu Met Ile Arg Phe Lys Tyr Gly Leu Pro

610 615 620

Glu Ile Thr Val Ser Ser Leu Ser Leu Tyr Thr Gly Ala Ile Leu Glu

625 630 635 640

Ala Asn Leu Leu Pro Pro Pro Glu Pro Lys Glu Ser Trp Arg Arg Ile

645 650 655

Met Asp Glu Leu Ser Val Ile Ser Cys Asp Val Tyr Arg Gly Tyr Val

660 665 670

Arg Glu Asn Lys Asp Phe Val Pro Tyr Phe Arg Ser Ala Thr Pro Glu

675 680 685

Gln Glu Leu Gly Lys Leu Pro Leu Gly Ser Arg Pro Ala Lys Arg Arg

690 695 700

Pro Thr Gly Gly Val Glu Ser Leu Arg Ala Ile Pro Trp Ile Phe Ala

705 710 715 720

Trp Thr Gln Asn Arg Leu Met Leu Pro Ala Trp Leu Gly Ala Gly Thr

725 730 735

Ala Leu Gln Lys Val Val Glu Asp Gly Lys Gln Ser Glu Leu Glu Ala

740 745 750

Met Cys Arg Asp Trp Pro Phe Phe Ser Thr Arg Leu Gly Met Leu Glu

755 760 765

Met Val Phe Ala Lys Ala Asp Leu Trp Leu Ala Glu Tyr Tyr Asp Gln

770 775 780

Arg Leu Val Asp Lys Ala Leu Trp Pro Leu Gly Lys Glu Leu Arg Asn

785 790 795 800

Leu Gln Glu Glu Asp Ile Lys Val Val Leu Ala Ile Ala Asn Asp Ser

805 810 815

His Leu Met Ala Asp Leu Pro Trp Ile Ala Glu Ser Ile Gln Leu Arg

820 825 830

Asn Ile Tyr Thr Asp Pro Leu Asn Val Leu Gln Ala Glu Leu Leu His

835 840 845

Arg Ser Arg Gln Ala Glu Lys Glu Gly Gln Glu Pro Asp Pro Arg Val

850 855 860

Glu Gln Ala Leu Met Val Thr Ile Ala Gly Ile Ala Ala Gly Met Arg

865 870 875 880

Asn Thr Gly

<210> 21

<211> 396

<212> PRT

<213> Escherichia coli

<220>

<221> PEPTIDE

<222> (1)..(396)

<223> aspartate aminotransferase

<400> 21

Met Phe Glu Asn Ile Thr Ala Ala Pro Ala Asp Pro Ile Leu Gly Leu

1 5 10 15

Ala Asp Leu Phe Arg Ala Asp Glu Arg Pro Gly Lys Ile Asn Leu Gly

20 25 30

Ile Gly Val Tyr Lys Asp Glu Thr Gly Lys Thr Pro Val Leu Thr Ser

35 40 45

Val Lys Lys Ala Glu Gln Tyr Leu Leu Glu Asn Glu Thr Thr Lys Asn

50 55 60

Tyr Leu Gly Ile Asp Gly Ile Pro Glu Phe Gly Arg Cys Thr Gln Glu

65 70 75 80

Leu Leu Phe Gly Lys Gly Ser Ala Leu Ile Asn Asp Lys Arg Ala Arg

85 90 95

Thr Ala Gln Thr Pro Gly Gly Thr Gly Ala Leu Arg Val Ala Ala Asp

100 105 110

Phe Leu Ala Lys Asn Thr Ser Val Lys Arg Val Trp Val Ser Asn Pro

115 120 125

Ser Trp Pro Asn His Lys Ser Val Phe Asn Ser Ala Gly Leu Glu Val

130 135 140

Arg Glu Tyr Ala Tyr Tyr Asp Ala Glu Asn His Thr Leu Asp Phe Asp

145 150 155 160

Ala Leu Ile Asn Ser Leu Asn Glu Ala Gln Ala Gly Asp Val Val Leu

165 170 175

Phe His Gly Cys Cys His Asn Pro Thr Gly Ile Asp Pro Thr Leu Glu

180 185 190

Gln Trp Gln Thr Leu Ala Gln Leu Ser Val Glu Lys Gly Trp Leu Pro

195 200 205

Leu Phe Asp Phe Ala Tyr Gln Gly Phe Ala Arg Gly Leu Glu Glu Asp

210 215 220

Ala Glu Gly Leu Arg Ala Phe Ala Ala Met His Lys Glu Leu Ile Val

225 230 235 240

Ala Ser Ser Tyr Ser Lys Asn Phe Gly Leu Tyr Asn Glu Arg Val Gly

245 250 255

Ala Cys Thr Leu Val Ala Ala Asp Ser Glu Thr Val Asp Arg Ala Phe

260 265 270

Ser Gln Met Lys Ala Ala Ile Arg Ala Asn Tyr Ser Asn Pro Pro Ala

275 280 285

His Gly Ala Ser Val Val Ala Thr Ile Leu Ser Asn Asp Ala Leu Arg

290 295 300

Ala Ile Trp Glu Gln Glu Leu Thr Asp Met Arg Gln Arg Ile Gln Arg

305 310 315 320

Met Arg Gln Leu Phe Val Asn Thr Leu Gln Glu Lys Gly Ala Asn Arg

325 330 335

Asp Phe Ser Phe Ile Ile Lys Gln Asn Gly Met Phe Ser Phe Ser Gly

340 345 350

Leu Thr Lys Glu Gln Val Leu Arg Leu Arg Glu Glu Phe Gly Val Tyr

355 360 365

Ala Val Ala Ser Gly Arg Val Asn Val Ala Gly Met Thr Pro Asp Asn

370 375 380

Met Ala Pro Leu Cys Glu Ala Ile Val Ala Val Leu

385 390 395

<210> 22

<211> 367

<212> PRT

<213> Escherichia coli

<220>

<221> PEPTIDE

<222> (1)..(367)

<223> aspartate-semialdehyde dehydrogenase

<400> 22

Met Lys Asn Val Gly Phe Ile Gly Trp Arg Gly Met Val Gly Ser Val

1 5 10 15

Leu Met Gln Arg Met Val Glu Glu Arg Asp Phe Asp Ala Ile Arg Pro

20 25 30

Val Phe Phe Ser Thr Ser Gln Leu Gly Gln Ala Ala Pro Ser Phe Gly

35 40 45

Gly Thr Thr Gly Thr Leu Gln Asp Ala Phe Asp Leu Glu Ala Leu Lys

50 55 60

Ala Leu Asp Ile Ile Val Thr Cys Gln Gly Gly Asp Tyr Thr Asn Glu

65 70 75 80

Ile Tyr Pro Lys Leu Arg Glu Ser Gly Trp Gln Gly Tyr Trp Ile Asp

85 90 95

Ala Ala Ser Ser Leu Arg Met Lys Asp Asp Ala Ile Ile Ile Leu Asp

100	105	110	
Pro Val Asn Gln Asp Val Ile Thr Asp Gly Leu Asn Asn Gly Ile Arg			
115	120	125	
Thr Phe Val Gly Gly Asn Cys Thr Val Ser Leu Met Leu Met Ser Leu			
130	135	140	
Gly Gly Leu Phe Ala Asn Asp Leu Val Asp Trp Val Ser Val Ala Thr			
145	150	155	160
Tyr Gln Ala Ala Ser Gly Gly Gly Ala Arg His Met Arg Glu Leu Leu			
165	170	175	
Thr Gln Met Gly His Leu Tyr Gly His Val Ala Asp Glu Leu Ala Thr			
180	185	190	
Pro Ser Ser Ala Ile Leu Asp Ile Glu Arg Lys Val Thr Thr Leu Thr			
195	200	205	
Arg Ser Gly Glu Leu Pro Val Asp Asn Phe Gly Val Pro Leu Ala Gly			
210	215	220	
Ser Leu Ile Pro Trp Ile Asp Lys Gln Leu Asp Asn Gly Gln Ser Arg			
225	230	235	240
Glu Glu Trp Lys Gly Gln Ala Glu Thr Asn Lys Ile Leu Asn Thr Ser			

245 250 255

Ser Val Ile Pro Val Asp Gly Leu Cys Val Arg Val Gly Ala Leu Arg

260 265 270

Cys His Ser Gln Ala Phe Thr Ile Lys Leu Lys Lys Asp Val Ser Ile

275 280 285

Pro Thr Val Glu Glu Leu Leu Ala Ala His Asn Pro Trp Ala Lys Val

290 295 300

Val Pro Asn Asp Arg Glu Ile Thr Met Arg Glu Leu Thr Pro Ala Ala

305 310 315 320

Val Thr Gly Thr Leu Thr Thr Pro Val Gly Arg Leu Arg Lys Leu Asn

325 330 335

Met Gly Pro Glu Phe Leu Ser Ala Phe Thr Val Gly Asp Gln Leu Leu

340 345 350

Trp Gly Ala Ala Glu Pro Leu Arg Arg Met Leu Arg Gln Leu Ala

355 360 365

<210> 23

<211> 933

<212> DNA

<213> Escherichia coli

<220>

<221> gene

<222> (1)..(933)

<223> homoserine O-succinyl transferase

<400> 23

atggttaaag ttatgcccc ggcttcagtg gccaatatga gcgtcgggtt tgatgtgctc 60

ggggcggcgg tgacacctgt tgatggtgca ttgctcggag atgtagtcac ggttgaggcg 120

gcagagacat tcagtctcaa caacctcgga cgctttgccg ataagctgcc gtcagaacca 180

cgggaaaata tcgtttatca gtgctgggag cgtttttgcc aggaactggg taagcaaatt 240

ccagtggcga tgacctgga aaagaatatg ccgatcgggt cgggcttagg ctccagtgcc 300

tgttcgggtg tcgcggcgct gatggcgatg aatgaacact gcggcaagcc gcttaatgac 360

actcgtttgc tggctttgat gggcgagctg gaaggccgta tctccggcag cattcattac 420

gacaacgtgg caccgtgttt ttcggtggt atgcagttga tgatcgaaga aaacgacatc 480

atcagccagc aagtgccagg gtttgatgag tggctgtggg tgctggcgta tccggggatt 540

aaagtctcga cggcagaagc cagggctatt ttaccggcgc agtatcgccg ccaggattgc 600

attgcgcacg ggcgacatct ggcaggcttc attcacgcct gctattcccg tcagcctgag 660

cttgccgca agctgatgaa agatgttatc gctgaaccct accgtgaacg gttactgcca 720

ggcttcggc aggcgcggca ggcggtcgcg gaaatcggcg cggtagcgag cggtatctcc 780

ggctccggcc cgaccttgtt cgctctgtgt gacaagccgg aaaccgccca gcgcgttgcc 840

gactggttgg gtaagaacta cctgcaaaat caggaaggtt ttgtcatat ttgccggctg 900

gatacggcgg gcgcacgagt actggaaaac taa 933

<210> 24

<211> 930

<212> DNA

<213> Artificial Sequence

<220>

<223> Variant polypeptide having homoserine O-acetyl transferase
activity, metA EL

<400> 24

atgccgattc gtgtgccgga cgagctaccc gccgtcaatt tcttgcgtga agaaaacgtc 60

tttgtgatga caacttctcg tgcgtctggt caggaaattc gtccacttaa ggttctgac 120

cttaacctga tgccgaagaa gattgaaact gaaaatcagt ttctg'gcct gcttcaaac 180

tcacctttgc aggtcgatat tcagctgttg cgcacgcatt cccgtgaatc gcgcaacacg 240

ccgcagagc atctgaacaa cttctactgt aacttgaag atattcagga tcagaacttt 300

gacggtttga ttgtaactgg tgcgccgctg gaactggtgg agtttaatga tgcgcttac 360

tggccgcaga tcaaacaggt gctggagtgg tcgaaagatc acgtcacctc gacgctgttt 420

gtctgctggg cggtagagc cgcgctcaat atcctctacg gcattcctaa gcaaactcgc 480

accgaaaaac tctctggcgt ttacgagcat catattctcc atcctcatgc gcttctgacg 540

cgtggccttg atgattcatt cctggcaccg cattcgcgct atgctgactt tccgacagcg 600

ttgattcgtg attacaccga tctggaatt ctggcagaga cggaagaagg ggatgcatat 660

ctgtttgccg gtaaagataa gcgcattgcc tttgtgacgg gccatcccga atatgatgcg 720

caaacgctgg cgcaggaatt tttccgcgat gtggaagccg gactagaccc ggatgtaccg 780

tataactatt tccgcacaa tgatccgcaa aatacaccgc gagcgagctg gcgtagtcac 840

ggtaatttac tgttaccaa ctggctcaac tattacgtct accagatcac gccatacgat 900

ctacggcaca tgaatccaac gctggattaa 930

<210> 25

<211> 930

<212> DNA

<213> Artificial Sequence

<220>

<223> Variant polypeptide having homoserine O-acetyl transferase
activity, metA ET

<400> 25

atgccgattc gtgtgccgga cgagctaccc gccgtcaatt tcttgcgtga agaaaacgtc 60

tttgtgatga caacttctcg tgcgtctggt caggaaattc gtccacttaa ggttctgatc 120

cttaacctga tgccgaagaa gattgaaact gaaaatcagt ttctg'gcct gctttcaaac 180

tcacctttgc aggtcgatat tcagctgttg cgcacgatt cccgtgaatc gcgcaacacg 240

ccgcagagc atctgaacaa cttctactgt aactttgaag atattcagga tcagaacttt 300

gacggtttga ttgtaactgg tgcgccgctg gaaaccgtgg agtttaatga tgcgcttac	360
tggccgcaga tcaaacaggt gctggagtgg tcgaaagatc acgtcacctc gacgctgttt	420
gtctgctggg cggtagagcg cgcgctcaat atcctctacg gcattcctaa gcaaactcgc	480
accgaaaaac tctctggcgt ttacgagcat catattctcc atcctcatgc gcttctgacg	540
cgtggctttg atgattcatt cctggcaccg cattcgcgct atgctgactt tccggcagcg	600
ttgattcgtg attacaccga tctggaaatt ctggcagaga cggaagaagg ggatgcatat	660
ctgtttgccg gtaaagataa gcgcattgcc tttgtgacgg gccatcccga atatgatgcg	720
caaacgctgg cgcaggaatt tttccgcgat gtggaagccg gactagaccc ggatgtaccg	780
tataactatt tccgcacaa tgatccgcaa aatacaccgc gagcgagctg gcgtagtcac	840
ggtaatttac tgtttacaa ctggctcaac tattacgtct accagatcac gccatacgat	900
ctacggcaca tgaatccaac gctggattaa	930

<210> 26

<211> 930

<212> DNA

<213> Artificial Sequence

<220>

<223> Variant polypeptide having homoserine O-acetyl transferase
activity, metA EH

<400> 26

atgccgattc gtgtgccgga cgagctaccc gccgtcaatt tcttgcgtga agaaaacgtc 60

tttgtgatga caacttctcg tgcgtctggt caggaaattc gtccacttaa ggttctgac 120

cttaacctga tgccgaagaa gattgaaact gaaaatcagt ttctgcgctt gcttcaaac 180

tcacctttgc aggtcgatat tcagctgttg cgcacgatt cccgtgaatc gcgcaacacg 240

ccgcagagc atctgaacaa cttctactgt aactttgaag atattcagga tcagaacttt 300

gacggtttga ttgtaactgg tgcgccgctg gaacatgtgg agtttaatga tgcgcttac 360

tggccgcaga tcaaacaggt gctggagtgg tcgaaagatc acgtcacctc gacgctgttt 420

gtctgctggg cggtagagc cgcgctcaat atcctctacg gcattcctaa gcaaactcgc 480

accgaaaaac tctctggcgt ttacgagcat catattctcc atcctcatgc gcttctgacg 540

cgtggctttg atgattcatt cctggcaccg cattcgcgct atgctgactt tccggcagcg 600

ttgattcgtg attacaccga tctggaaatt ctggcagaga cggaagaagg ggatgcatat 660

ctgtttgccg gtaaagataa gcgcattgcc tttgtgacgg gccatcccga atatgatgcg 720

caaacgctgg cgcaggaatt tttccgcgat gtggaagccg gactagaccc ggatgtaccg 780

tataactatt tcccgcacaa tgatccgcaa aatacaccgc gagcgagctg gcgtagtcac 840

ggtaatttac tgtttacaa ctggctcaac tattacgtct accagatcac gccatacgat 900

ctacggcaca tgaatccaac gctggattaa 930

<210> 27

<211> 2652

<212> DNA

<213> Escherichia coli

<220>

<221> gene

<222> (1)..(2652)

<223> phosphoenolpyruvate carboxylase

<400> 27

atgaacgaac aatattccgc attgcgtagt aatgtcagta tgctcggcaa agtgctggga 60

gaaacatca aggatgcgtt gggagaacac attcttgaac gcgtagaaac tatccgtaag	120
ttgtcgaaat cttcacgcgc tggcaatgat gctaaccgcc aggagttgct caccacctta	180
caaaatttgt cgaacgacga gctgctgccc gttgcgcgtg cgtttagtca gttcctgaac	240
ctggccaaca ccgccgagca ataccacagc atttcgccga aaggcgaagc tgccagcaac	300
ccggaagtga tcgcccgcac cctgcgtaaa ctgaaaaacc agccggaact gagcgaagac	360
accatcaaaa aagcagtgga atcgctgtcg ctggaactgg tcctcacggc tcaccaacc	420
gaaattaccc gtcgtacact gatccacaaa atggtggaag tgaacgcctg tttaaacag	480
ctcgataaca aagatatcgc tgactacgaa cacaaccagc tgatgcgtcg cctgcgccag	540
ttgatcgccc agtcatggca taccgatgaa atccgtaagc tgcgtccaag cccggtagat	600
gaagccaaat ggggctttgc cgtagtggaa aacagcctgt ggcaaggcgt accaaattac	660
ctgcgcgaac tgaacgaaca actggaagag aacctcggt acaaactgcc cgtcgaattt	720
gttcgggtcc gttttacttc gtggatgggc ggcgaccgcg acggcaacc gaacgtcact	780
gccgatatca cccgccacgt cctgtactc agccgtgga aagccaccga tttgttcctg	840

aaagatattc aggtgctggt ttctgaactg tcgatggtg aagcgacccc tgaactgctg	900
gcgctggttg gcgaagaagg tgccgcagaa ccgtatcgct atctgatgaa aaacctgcgt	960
tctcgctga tggcgacaca ggcatggctg gaagcgcgcc tgaaaggcga agaactgcca	1020
aaaccagaag gcctgtgac acaaaacgaa gaactgtggg aaccgtcta cgcttgctac	1080
cagtcacttc aggcgtgtgg catgggtatt atcgccaacg gcgatctgct cgacaccctg	1140
cgccgcgtga aatgtttcgg cgtaccgtg gtccgtattg atatccgtca ggagagcacg	1200
cgctataccg aagcgctggg cgagctgacc cgctacctg gtatcggcga ctacgaaagc	1260
tggtcagagg ccgacaaaca ggcgctctg atccgcgaac tgaactcaa acgtccgctt	1320
ctgccgcga actggcaacc aagcgccgaa acgcgcgaag tgctcgatac ctgccaggtg	1380
attgccgaag caccgcaagg ctccattgcc gcctacgtga tctcgatggc gaaaacgccg	1440
tccgacgtac tggctgtcca cctgtgctg aaagaagcgg gtatcgggtt tgcgatgccg	1500
gttgctccgc tgtttgaaac cctcgatgat ctgaacaacg ccaacgatgt catgaccag	1560
ctgctcaata ttgactggta tcgtggcctg attcagggca aacagatggt gatgattggc	1620
tattccgact cagcaaaaga tgcgggagtg atggcagctt cctgggcgca atatcaggca	1680

caggatgcat taatcaaac ctgcgaaaaa gcgggtattg agctgacgtt gttccacggt	1740
cgcggcgggt ccattggtcg cggcggcgca cctgctcatg cggcgtgct gtcacaaccg	1800
ccaggaagcc tgaaaggcgg cctgcgcgta accgaacagg gcgagatgat ccgctttaa	1860
tatggtctgc cagaaatcac cgtcagcagc ctgtcgctt ataccggggc gattctggaa	1920
gccaacctgc tgccaccgcc ggagccgaaa gagagctggc gtcgcattat ggatgaactg	1980
tcagtcatct cctgcgatgt ctaccgcggc tacgtacgtg aaaacaaaga tttgtgcct	2040
tacttccgct ccgctacgcc ggaacaagaa ctgggcaaac tgccgttggg ttcacgtccg	2100
gcgaaacgtc gcccaaccgg cggcgtcgag tcactacgcg ccattccgtg gatcttcgcc	2160
tggacgcaaa accgtctgat gctccccgcc tggctgggtg caggtacggc gctgcaaaaa	2220
gtggtcgaag acggcaaaca gagcgagctg gaggctatgt gccgcgattg gccattcttc	2280
tcgacgctc tcggcatgct ggagatggtc ttcgcaaag cagacctgtg gctggcggaa	2340
tactatgacc aacgcctggt agacaaagca ctgtggccgt taggtaaaga gttacgcaac	2400
ctgcaagaag aagacatcaa agtggtgctg gcgattgcca acgattcca tctgatggcc	2460

gatctgccgt ggattgcaga gtctattcag ctacggaata ttacaccga cccgctgaac 2520

gtattgcagg ccgagttgct gcaccgtcc cgccaggcag aaaaagaagg ccaggaaccg 2580

gacctcgcg tcgaacaagc gttaatggc actattgccg ggattgcggc aggtatgcgt 2640

aataccggct aa 2652

<210> 28

<211> 1191

<212> DNA

<213> Escherichia coli

<220>

<221> gene

<222> (1)..(1191)

<223> aspartate aminotransferase

<400> 28

atgtttgaga acattaccgc cgctcctgcc gaccgattc tgggcctggc cgatctgtt 60

cgtgccgatg aacgtcccgg caaaattaac ctccgggattg gtgtctataa agatgagacg 120

ggcaaaaccc cggctactgac cagcgtgaaa aaggctgaac agtatctgct cgaaaatgaa 180

accaccaaaa attacctcgg cattgacggc atccctgaat ttggtcgtg cactcaggaa	240
ctgctgtttg gtaaaggtag cgccctgac aatgacaaac gtgctgcac ggcacagact	300
ccggggggca ctggcgact acgcgtggct gccgatttcc tggcaaaaaa taccagcgtt	360
aagcgtgtgt gggtagagcaa cccaagctgg ccgaaccata agagcgtctt taactctgca	420
ggtctggaag ttcgtgaata cgcttattat gatgcggaaa atcacactct tgacttcgat	480
gcactgatta acagcctgaa tgaagctcag gctggcgacg tagtgctgtt ccatggctgc	540
tgccataacc caaccgtat cgaccctacg ctggaacaat ggcaaacact ggcacaactc	600
tccgttgaga aaggctggtt accgctgtt gacttcgctt accagggttt tgcccgtggt	660
ctggaagaag atgctgaagg actgcgcgct ttcgcgcta tgcataaaga gctgattgtt	720
gccagttcct actctaaaaa cttggcctg tacaacgagc gtgttggcgc ttgtactctg	780
gttgctgccg acagtgaac cgttgatcgc gcattcagcc aaatgaaagc ggcgattcgc	840
gctaactact ctaaccacc agcacacggc gcttctgtt ttgccaccat cctgagcaac	900
gatgcgttac gtgcgatttg ggaacaagag ctgactgata tgcgccagcg tattcagcgt	960
atgcgtcagt tgttcgtcaa tacgtgcag gaaaaaggcg caaacgcga cttcagcttt	1020

atcatcaaac agaacggcat gttctccttc agtggcctga caaaagaaca agtgctgcgt 1080

ctgcgcgaag agtttggcgt atatgcggtt gcttctggtc gcgtaaatgt ggccgggatg 1140

acaccagata acatggctcc gctgtgcgaa gcgattgtgg cagtgcgtga a 1191

<210> 29

<211> 1104

<212> DNA

<213> Escherichia coli

<220>

<221> gene

<222> (1)..(1104)

<223> aspartate-semialdehyde dehydrogenase

<400> 29

atgaaaaatg ttggttttat cggctggcgc ggtatggtcg gctccgttct catgcaacgc 60

atggttgaag agcgcgactt cgacgccatt cgcctgtct tcttttctac ttctcagctt 120

ggccaggctg cgccgtcttt tggcggaacc actggcacac ttcaggatgc ctttgatctg 180

gaggcgctaa aggccctcga tatcatttg acctgtcagg gcggcgatta taccaacgaa 240

atctatccaa agcttcgtga aagcggatgg caaggttact ggattgacgc agcatcgtct	300
ctgcgcatga aagatgacgc catcatcatt cttgaccccg tcaatcagga cgtcattacc	360
gacggattaa ataatggcat caggactttt gttggcgga actgtaccgt aagcctgatg	420
ttgatgtcgt tgggtggttt attcgccaat gatcttgttg attgggtgtc cgttgcaacc	480
taccaggccg cttccggcgg tggcgcgga catatgcgtg agttattaac ccagatgggc	540
catctgtatg gccatgtggc agatgaactc gcgaccccg cctctgctat tctcgatac	600
gaacgcaaag tcacaacctt aaccgtagc ggtgagctgc cggtgataa ctttggcgtg	660
ccgctggcgg gtagcctgat tccgtggatc gacaaacagc tcgataacgg tcagagccgc	720
gaagagtga aagggcaggc ggaaccaac aagatcctca acacatcttc cgtaattccg	780
gtagatggtt tatgtgtcgc tgcggggca ttgcgtgcc acagccaggc attcactatt	840
aaattgaaaa aagatgtgtc tattccgacc gtggaagaac tgctggctgc gcacaatccg	900
tgggcgaaag tcgttccgaa cgatcgggaa atcactatgc gtgagctaac cccagctgcc	960
gttaccggca cgctgaccac gccggtaggc cgcctgcgta agctgaatat gggaccagag	1020

ttcctgtcag cctttaccgt gggcgaccag ctgctgtggg gggccgcgga gccgctgcgt 1080

cggatgcttc gtcaactggc gtaa 1104

<210> 30

<211> 70

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 30

ttactctggt gcctgacatt tcaccgacaa agcccaggga acttcacac gtgtaggctg 60

gagctgcttc 70

<210> 31

<211> 70

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 31

ttacccttg ttgcagccc ggaagccatt ttccaggtcg gcaattaaat catatgaata 60

tcctccttag 70

<210> 32

<211> 70

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 32

aaagaatatg ccgatcggtt cgggcttagg ctccagtgcc tggtcggtgg gtgtaggctg 60

gagctgcttc 70

<210> 33

<211> 70

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 33

agacaaccga catcgctttc aacattggcg accggagccg ggaaggcaaa catatgaata 60

tcctccttag 70

<210> 34

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 34

aattgatatc atgccgattc gtgtgccgg 29

<210> 35

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 35

aattaagctt ttaatccagc gttggattca tgtg 34

<210> 36

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 36

ttgtaactgg tgcgccgctg gaactggtgg ggtttaatga tgtc 44

<210> 37

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 37

gacatcatta aacccaccca gttccagcgg cgcaccagtt acaa 44

<210> 38

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 38

tgtaactggt gcgccgctgg aacatgtggg gtttaatgat gtcg 44

<210> 39

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 39

cgacatcatt aaacccaca tgttcagcg gcgcaccagt taca 44

<210> 40

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 40

tttcgaaac gtacctcagc aggtgtaggc tggagctgct tc 42

<210> 41

<211> 43

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 41

gaataaaatt tattcacctg ctgcatatga atacctcct tag 43

<210> 42

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 42

aattgatatc atgccgattc gtgtgccgg 29

<210> 43

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 43

aattaagcct gctgaggtac gtttcgg

27

<210> 44

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 44

cagcaggtga ataaatttta ttc

23

<210> 45

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 45

cgcgaatgga agctgtttcc

20

<210> 46

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 46

gccggaattc tgcggatgc gatactgcg c

31

<210> 47

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 47

gaaggagctc agaaaaccct cgcgcaaaag

30

<210> 48

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 48

gccggagctc tgcggatgc gatacttgcg c

31

<210> 49

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 49

gaagggtacc agaaaaccct cgcgcaaaag

30

<210> 50

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 50

tccgagctca taagcgtagc gcatcaggca

30

<210> 51

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 51

tccgagctcg tccacctatg ttgactacat

30

<210> 52

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 52

ccggaattcc caggagagca ataagca 27

<210> 53

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 53

ctagtctaga tgctctattt aactcccg 28

<210> 54

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 54

ctagtctaga ccaggagagc aataagca 28

<210> 55

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 55

ccggaattct gctctattta actcccg 27

<210> 56

<211> 70

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 56

aggcgctaag gagaccttaa atggctgata caaaagcaaa actcacctc tgtaggctgg 60

agctgcttcg 70

<210> 57

<211> 70

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 57

gggttaaaat attacaact tagcaatcaa ccattaacgc ttgatatcgc atgggaatta 60

gccatgtcc

70

<210> 58

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 58

cctttctata actgcgctc at

22

<210> 59

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 59

aggggtatag ctaccaga a

21

<210> 60

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 60

gaaggcaaat ttaagttccg 20

<210> 61

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 61

cgaagcagct ccagcctaca ggtatagata gacgtcattt 40

<210> 62

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 62

cggcgcgctg gcggcggttcg cgcacgactc gctggatgtt aa

42

<210> 63

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 63

ttaacatcca gcgagtcgtg cgcgaacgcc gccagcgcgc cg

42

<210> 64

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 64

cgcgttccgc ctgctgtcgg cgatgccgac catggccgcg at 42

<210> 65

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 65

atcgcggccca tggtcggcat cgccgacagc aggcggaacg cg 42

<210> 66

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 66

tcctgaatat gatgttctcc gcgccgtgcg aaccgtatga 40

<210> 67

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 67

tcatacggtt cgcacggcgc ggagaacatc atattcagga 40

<210> 68

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 68

aaatgacgtc tatctatacc ttaggctgg agctgcttcg 40

<210> 69

<211> 76

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 69

gcaaaactaa attattgga tcatgaattt gttgtatgat gaataaaata taggggatgg 60

gaattagcca tgggcc 76

<210> 70

<211> 67

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 70

ccatggagga ggaattaacc atgcagtggg ggtgggtggg gtgcgataac agctgtatcc 60

ccgttga 67

<210> 71

<211> 67

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 71

aagcttagga ggaattaacc atgcagtggg ggtgggtggg gtgcatgca aatttaagtt 60

ccggcag 67

CLAIMS

1. A microorganism of *Escherichia* sp. producing *O*-acetyl homoserine, wherein the endogenous activity of citrate synthase is attenuated or inactivated.
2. The microorganism of *Escherichia* sp. according to claim 1, wherein the microorganism with the attenuated endogenous activity of citrate synthase has an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2.
3. The microorganism of *Escherichia* sp. according to claim 1, wherein the activity of cystathionine gamma synthase, homoserine kinase, or both is further attenuated or inactivated compared to their endogenous activities.
4. The microorganism of *Escherichia* sp. according to claim 1, wherein the activity of homoserine *O*-acetyltransferase is further introduced or enhanced, or the endogenous homoserine *O*-succinyltransferase is further modified to have the activity of homoserine *O*-acetyltransferase.
5. The microorganism of *Escherichia* sp. according to claim 1, wherein the activity of at least one protein selected from the group consisting of phosphoenolpyruvate carboxylase, aspartate aminotransferase, and aspartate semialdehyde dehydrogenase is further introduced or enhanced.
6. The microorganism of *Escherichia* sp. according to claim 1, wherein the microorganism is *Escherichia coli*.
7. A method for producing *O*-acetyl homoserine, comprising:
 - (a) culturing the microorganism of any of claims 1 to 6; and
 - (b) recovering *O*-acetyl homoserine produced during the cultivation of the microorganism.